<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        360-334-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PROGRAF 5 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TACROLIMUS
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4033.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Astellas Pharma" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Astellas Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Prograf belongs to a group of medicines called immunosuppressants. Following your organ transplant (e.g. liver, kidney, heart), your body&rsquo;s immune system will try to reject the new organ. Prograf is used to control your body&rsquo;s immune response enabling your body to accept the transplanted organ.</p><p>Prograf is often used in combination with other medicines that also suppress the immune system.</p><p>You may also be given Prograf for an ongoing rejection of your transplanted liver, kidney, heart or other organ or if any previous treatment you were taking was unable to control this immune response after your transplantation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Prograf</strong></p><ul><li>If you are allergic (hypersensitive) to tacrolimus or any of the other ingredients of Prograf (listed in section 6).</li><li>If you are allergic (hypersensitive) to any antibiotic belonging to the subgroup of macrolide antibiotics (e.g. erythromycin, clarithromycin, josamycin).&nbsp;</li></ul><p><strong>Warnings and precautions </strong><br />Talk to your doctor or pharmacist before taking Prograf.</p><ul><li>You will need to take Prograf every day as long as you need immunosuppression to prevent rejection of your transplanted organ. You should keep in regular contact with your doctor.</li><li>Whilst you are taking Prograf your doctor may want to carry out a number of tests (including blood, urine, heart function, visual and neurological tests) from time to time. This is quite normal and will help your doctor to decide on the most appropriate dose of Prograf for you.</li><li>Please avoid taking any herbal remedies, e.g. St. John&rsquo;s wort (Hypericum perforatum) or any other herbal products as this may affect the effectiveness and the dose of Prograf that you need to receive. If in doubt please consult your doctor prior to taking any herbal products or remedies.</li><li>If you have liver problems or have had a disease which may have affected your liver, please tell your doctor as this may affect the dose of Prograf that you receive.</li><li>If you feel strong abdominal pain accompanied or not with other symptoms, such as chills, fever, nausea or vomiting.</li><li>If you have diarrhoea for more than one day, please tell your doctor, because it might be necessary to adapt the dose of Prograf that you receive.</li><li>If you have an alteration of the electrical activity of your heart called &ldquo;QT prolongation&rdquo;.</li><li>Limit your exposure to sunlight and UV light whilst taking Prograf by wearing appropriate protective clothing and using a sunscreen with a high sun protection factor. This is because of the potential risk of malignant skin changes with immunosuppressive therapy.</li><li>If you need to have any vaccinations, please inform your doctor beforehand. Your doctor will advise you on the best course of action.</li><li>Patients treated with Prograf have been reported to have an increased risk of developing lymphoproliferative disorders (see section 4). Ask your doctor for specific advice on these disorders.</li><li>If you have or have had damage to the smallest blood vessels, known as thrombotic microangiopathy/thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome. Tell your doctor if you develop fever, bruising under the skin (which may appear as red dots), unexplained tiredness, confusion, yellowing of the skin or eyes, reduced urine output, vision loss and seizures (see section 4). When tacrolimus is taken together with sirolimus or everolimus, the risk of developing these symptoms may increase.</li></ul><p><strong>Precaution for handling:</strong><br />Direct contact with any part of your body like your skin or eyes, or breathing in of injection solutions, powder or granules contained in tacrolimus products should be avoided during preparation. If such contact occurs, wash the skin and eyes.</p><p><strong>Other medicines and Prograf</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription and herbal remedies.</p><p>Prograf must not be taken with ciclosporin.</p><p>If you need to attend a doctor other than your transplant specialist, tell the doctor that you are taking tacrolimus. Your doctor may need to consult your transplant specialist if you should use another medicine that could increase or decrease your tacrolimus blood level.</p><p>Prograf blood levels can be affected by other medicines you take, and blood levels of other medicines can be affected by taking Prograf which may require interruption, an increase or a decrease in Prograf dose.</p><p>Some patients have experienced increases in tacrolimus blood levels while taking other medicines. This could lead to serious side effects, such as kidney problems, nervous system problems, and heart rhythm disturbances (see section 4).</p><p>An effect on the Prograf blood levels may occur very soon after starting the use of another medicine, therefore frequent continued monitoring of your Prograf blood level may be needed within the first few days of starting another medicine and frequently while treatment with the other medicine continues. Some other medicines may cause tacrolimus blood levels to decrease, which could increase the risk of rejecting the transplanted organ.</p><p>In particular, you should tell your doctor if you are taking or have recently taken medicines with active substances like:</p><ul><li>Antifungal medicines and antibiotics, particularly so-called macrolide antibiotics, used to treat infections e.g. ketoconazole, fluconazole, itraconazole, posaconazole, voriconazole, clotrimazole, isavuconazole, miconazole, caspofungin, telithromycin, erythromycin, clarithromycin, josamycin, azithromycin, rifampicin, rifabutin, isoniazid and flucloxacillin</li><li>Letermovir, used to prevent illness caused by CMV (human cytomegalovirus).</li><li>HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir), the booster medicine cobicistat, and combination tablets, or HIV non‐nucleoside reverse transcriptase inhibitors (efavirenz, etravirine, nevirapine) used to treat HIV infection.</li><li>HCV protease inhibitors (e.g. telaprevir, boceprevir, and the combination ombitasvir/paritaprevir/ritonavir with or without dasabuvir, elbasvir/grazoprevir, and glecaprevir/pibrentasvir), used to treat hepatitis C infection.</li><li>Nilotinib and imatinib, idelalisib, ceritinib, crizotinib, apalutamide, enzalutamide, or mitotane (used to treat certain cancers).</li><li>Mycophenolic acid, used to suppress the immune system to prevent transplant rejection.</li><li>Medicines for stomach ulcer and acid reflux (e.g. omeprazole, lansoprazole or cimetidine).</li><li>Antiemetics, used to treat nausea and vomiting (e.g. metoclopramide).</li><li>Magnesium-aluminium-hydroxide (antacid), used to treat heartburn.</li><li>Hormone treatments with ethinylestradiol (e.g. the oral contraceptive pill) or danazol.</li><li>Medicines for high blood pressure or heart problems such as nifedipine, nicardipine, diltiazem and verapamil.</li><li>Anti-arrhythmic medicines (amiodarone) used to control arrhythmia (uneven beating of the heart).</li><li>Medicines known as &ldquo;statins&rdquo; used to treat elevated cholesterol and triglycerides.</li><li>The anti-epileptic medicines carbamazepine, phenytoin or phenobarbital.</li><li>Metamizole, used to treat pain and fever.</li><li>The corticosteroids prednisolone and methylprednisolone.</li><li>The anti-depressant nefazodone.</li><li>Herbal preparations containing St. John&rsquo;s Wort (Hypericum perforatum) or extracts of Schisandra sphenanthera.</li><li>Cannabidiol (uses amongst others include treatment of seizures).</li></ul><p>Tell your doctor if you are receiving treatment for hepatitis C. The drug treatment for hepatitis C may change your liver function and may affect blood levels of tacrolimus. Tacrolimus blood levels may fall or may increase depending on the medicines prescribed for hepatitis C. Your doctor may need to closely monitor tacrolimus blood levels and make necessary adjustments of Prograf dose after you start treatment for hepatitis C.</p><p>Tell your doctor if you are taking or need to take ibuprofen, amphotericin B, antibiotics (cotrimoxazole, vancomycin, or so-called aminoglycoside antibiotics such as gentamicin), or antivirals (e.g. acyclovir, ganciclovir, cidofovir, or foscarnet). These may worsen kidney or nervous system problems when taken together with Prograf.</p><p>Tell your doctor if you are taking sirolimus or everolimus. When tacrolimus is taken together with sirolimus or everolimus, the risk of developing thrombotic microangiopathy, thrombotic thrombocytopenic purpura, and haemolytic uraemic syndrome may increase (see section 4).</p><p>Your doctor also needs to know if you are taking potassium supplements or potassium-sparing diuretics (e.g., amiloride, triamterene, or spironolactone), or the antibiotics trimethoprim or cotrimoxazole that may increase levels of potassium in your blood, certain pain killers (so-called NSAIDs, e.g. ibuprofen), anticoagulants, or oral medication for diabetic treatment, while you receive Prograf.</p><p>If you need to have any vaccinations, please inform your doctor beforehand.</p><p><strong>Prograf with food and drink</strong><br />You should generally take Prograf on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. Grapefruit and grapefruit juice should be avoided while taking Prograf.</p><p><strong>Pregnancy and breast-feeding </strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Prograf is excreted into breast milk. Therefore you should not breast-feed whilst receiving Prograf.</p><p><strong>Driving and using machines </strong><br />Do not drive or use any tools or machines if you feel dizzy or sleepy, or have problems seeing clearly after taking Prograf. These effects are more frequently observed if Prograf is taken in conjunction with alcohol use.</p><p><strong>Prograf contains lactose monohydrate, sodium and lecithin (soya)</strong><br />Prograf contains lactose monohydrate. Each hard capsule of Prograf 1 mg and 5 mg Hard Capsules contains 61.35 mg or 123.60 mg lactose monohydrate; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Prograf contains sodium. Each hard capsule of Prograf 1 mg and 5 mg Hard Capsules contains 0.091 mg or 0.453 mg sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>The printing ink used on Prograf 1 mg Hard Capsules contains soya lecithin. Each hard capsule contains 0.0007 mg soya lecithin. If you are allergic to peanut or soya, talk to your doctor to determine whether you should use this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Always take Prograf exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p style="text-align:justify">Make sure that you receive the same tacrolimus medicine every time you collect your prescription, unless your transplant specialist has agreed to change to a different tacrolimus medicine.</p><p style="text-align:justify">This medicine should be taken twice a day. If the appearance of this medicine is not the same as usual, or if dosage instructions have changed, speak to your doctor or pharmacist as soon as possible to make sure that you have the right medicine.</p><p style="text-align:justify">The starting dose to prevent the rejection of your transplanted organ will be determined by your doctor calculated according to your body weight. Initial doses just after transplantation will generally be in the range of 0.075 &ndash; 0.30 mg per kg body weight per day&nbsp; depending on the transplanted organ.</p><p style="text-align:justify">Your dose depends on your general condition and on which other immunosuppressive medication you are taking. Regular blood tests by your doctor will be required to define the correct dose and to adjust the dose from time to time. Your doctor will usually reduce your Prograf dose once your condition has stabilised. Your doctor will tell you exactly how many capsules to take and how often.</p><p style="text-align:justify">Prograf is taken orally twice daily, usually in the morning and evening. You should generally take Prograf on an empty stomach or at least 1 hour before or 2 to 3 hours after the meal. The capsules should be swallowed whole with a glass of water. Take the capsules immediately following removal from the bottel. Avoid grapefruit and grapefruit juice while taking Prograf. Do not swallow the desiccant contained in the foil wrapper.</p><p style="text-align:justify"><strong>If you take more </strong><strong>Prograf </strong><strong>than you should</strong><br />If you have accidentally taken too much Prograf see your doctor or contact your nearest hospital emergency department immediately.</p><p style="text-align:justify"><strong>If you forget to take </strong><strong>Prograf</strong><br />Do not take a double dose to make up for forgotten individual doses.</p><p style="text-align:justify">If you have forgotten to take your Prograf capsules, wait until it is time for the next dose, and then continue as before.</p><p style="text-align:justify"><strong>If you stop taking </strong><strong>Prograf</strong><br />Stopping your treatment with Prograf may increase the risk of rejection of your transplanted organ. Do not stop your treatment unless your doctor tells you to do so.</p><p style="text-align:justify">If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Prograf can cause side effects, although not everybody gets them.</p><p>Prograf reduces your body&rsquo;s own defence mechanism to stop you rejecting your transplanted organ. Consequently, your body will not be as good as usual at fighting infections. So if you are taking Prograf you may therefore catch more infections than usual such as infections of the skin, mouth, stomach and intestines, lungs and urinary tract.</p><p>Some infections could be serious or fatal and may include infections caused by bacteria, viruses, fungi, parasites, or other infections.</p><p>Tell your doctor immediately if you get signs of an infection including:</p><ul><li>Fever, cough, sore throat, feeling weak or generally unwell</li><li>Memory loss, trouble thinking, difficulty walking or loss of vision&nbsp; these may be due to a very rare, serious brain infection, which can be fatal (Progressive Multifocal Leukoencephalopathy or PML)</li></ul><p><strong><em>Severe side effects may occur, including the ones listed below. Tell your doctor immediately if you have or suspect you may have any of the following serious side effects:</em><br />Serious common side effects (may affect up to 1 in 10 people):</strong></p><ul><li>Gastrointestinal perforation: strong abdominal pain accompanied or not with other symptoms, such as chills, fever, nausea or vomiting.</li><li>Insufficient function of your transplanted organ.&nbsp;</li><li>Blurred vision.</li></ul><p><strong>Serious uncommon side effects (may affect up to 1 in 100 people):</strong></p><ul><li>Thrombotic microangiopathy (damage to the smallest blood vessels) including haemolytic uraemic syndrome, a condition with the following symptoms: low or no urine output (acute renal failure), extreme tiredness, yellowing of the skin or eyes (jaundice) and abnormal bruising or bleeding and signs of infection.</li></ul><p><strong>Serious rare side effects (may affect up to 1 in 1,000 people):</strong></p><ul><li>Thrombotic Thrombocytopenic Purpura a condition involving damage to the smallest blood vessels and characterised by fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice), with symptoms of acute renal failure (low or no urine output), vision loss and seizures.</li><li>Toxic epidermal necrolysis: erosion and blistering of skin or mucous membranes, red swollen skin that can detach in large parts of the body.</li><li>Blindness.</li></ul><p><strong>Serious very rare side effects (may affect up to 1 in 10,000 people):</strong></p><ul><li>Stevens-Johnson syndrome: unexplained widespread skin pain, facial swelling, serious illness with blistering of skin, mouth, eyes and genitals, hives, tongue swelling, red or purple skin rash that spreads, skin shedding.</li><li>Torsades de Pointes: change in the heart frequency that can be accompanied or not of symptoms, such as chest pain (angina), faint, vertigo or nausea, palpitations (feeling the heartbeat) and difficulty breathing.</li></ul><p><strong>Serious side effects - frequency not known (frequency cannot be estimated from the available data):</strong></p><ul><li>Opportunistic infections (bacterial, fungal, viral and protozoal): prolonged diarrhea, fever and sore throat.</li><li>Benign and malignant tumours have been reported following treatment as a result of immunosuppression.</li><li>Cases of pure red cell aplasia (a very severe reduction in red blood cell counts), haemolytic anaemia (decreased number of red blood cells due to abnormal breakdown accompanied with tiredness) and febrile neutropenia (a decrease in the type of white blood cells which fight infection, accompanied by fever) have been reported. It is not known exactly how often these side effects occur. You may have no symptoms or depending on the severity of the condition, you may feel: fatigue, apathy, abnormal paleness of the skin (pallor), shortness of breath, dizziness, headache, chest pain and coldness in hands and feet.</li><li>Cases of agranulocytosis (a severely lowered number of white blood cells accompanied with ulcers in the mouth, fever and infection(s)). You may have no symptoms or you may feel sudden fever, rigors and sore throat.</li><li>Allergic and anaphylactic reactions with the following symptoms: a sudden itchy rash (hives), swelling of hands, feet, ankle, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing) and you may feel you are going to faint.</li><li>Posterior Reversible Encephalopathy Syndrome (PRES): headache, confusion, mood changes, fits, and disturbances of your vision. These could be signs of a disorder known as posterior reversible encephalopathy syndrome, which has been reported in some patients treated with tacrolimus.</li><li>Optic neuropathy (abnormality of the optic nerve): problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or restriction of your field of vision.</li></ul><p><strong><em>The side effects listed below may also occur after receiving Prograf and could be serious: </em><br />Very common side effects (may affect more than 1 in 10 people): </strong></p><ul><li>Increased blood sugar, diabetes mellitus, increased potassium in the blood</li><li>Difficulty in sleeping</li><li>Trembling, headache</li><li>Increased blood pressure</li><li>Liver function tests abnormal</li><li>Diarrhoea, nausea</li><li>Kidney problems.</li></ul><p><strong>Common side effects (may affect up to 1 in 10 people): </strong></p><ul><li>Reduction in blood cell counts (platelets, red or white blood cells), increase in white blood cell counts, changes in red blood cell counts (seen in blood tests).</li><li>Reduced magnesium, phosphate, potassium, calcium or sodium in the blood, fluid overload, increased uric acid or lipids in the blood, decreased appetite, increased acidity of the blood, other changes in the blood salts</li><li>Anxiety symptoms, confusion and disorientation, depression, mood changes, nightmare, hallucination, mental disorders</li><li>Fits, disturbances in consciousness, tingling and numbness (sometimes painful) in the hands and feet, dizziness, impaired writing ability, nervous system disorders</li><li>Increased sensitivity to light, eye disorders</li><li>Ringing sound in your ears</li><li>Reduced blood flow in the heart vessels, faster heartbeat</li><li>Bleeding, partial or complete blocking of blood vessels, reduced blood pressure</li><li>Shortness in breath, changes in the lung tissue, collection of liquid around the lung, inflammation of the pharynx, cough, flu-like symptoms</li><li>Inflammations or ulcers causing abdominal pain or diarrhoea, bleedings in the stomach, inflammations or ulcers in the mouth, collection of fluid in the belly, vomiting, abdominal pains, indigestion, constipation, flatulence, bloating, loose stools, stomach problems</li><li>Changes in liver enzymes and function, yellowing of the skin due to liver problems, liver tissue damage and inflammation of the liver</li><li>Itching, rash, hair loss, acne, increased sweating</li><li>Pain in joints, limbs, back and feet, muscle spasms</li><li>Insufficient function of the kidneys, reduced production of urine, impaired or painful urination</li><li>General weakness, fever, collection of fluid in your body, pain and discomfort, increase of the enzyme alkaline phosphatase in your blood, weight gain, feeling of temperature disturbed.</li></ul><p><strong>Uncommon side effects (may affect up to 1 in 100 people): </strong></p><ul><li>Changes in blood clotting, reduction in all blood cell counts</li><li>Dehydration</li><li>Reduced protein or sugar in the blood, increased phosphate in the blood</li><li>Coma, bleeding in the brain, stroke, paralysis, brain disorder, speech and language abnormalities, memory problems</li><li>Blurring of the vision due to abnormality in the lens of the eye</li><li>Impaired hearing</li><li>Irregular heartbeat, stop of heartbeat, reduced performance of your heart, disorder of the heart muscle, enlargement of the heart muscle, stronger heartbeat, abnormal ECG, heart rate and pulse abnormal</li><li>Blood clot in a vein of a limb, shock</li><li>Difficulties in breathing, respiratory tract disorders, asthma</li><li>Obstruction of the gut, increased blood level of the enzyme amylase, reflux of stomach content in your throat, delayed emptying of the stomach</li><li>Dermatitis, burning sensation in the sunlight</li><li>Joint disorders</li><li>Inability to urinate, painful menstruation and abnormal menstrual bleeding</li><li>Failure of some organs, influenza like illness, increased sensitivity to heat and cold, feeling of pressure on your chest, jittery or abnormal feeling, increase of the enzyme lactate dehydrogenase in your blood, weight loss.</li></ul><p><strong>Rare side effects (may affect up to 1 in 1,000 people): </strong></p><ul><li>Small bleedings in your skin due to blood clots</li><li>Increased muscle stiffness</li><li>Blindness</li><li>Deafness</li><li>Collection of fluid around the heart</li><li>Acute breathlessness</li><li>Cyst formation in your pancreas</li><li>Problems with blood flow in the liver</li><li>Increased hairiness</li><li>Thirst, fall, feeling of tightness in your chest, decreased mobility, ulcer.</li></ul><p><strong>Very rare side effects (may affect up to 1 in 10,000 people): </strong></p><ul><li>Muscular weakness</li><li>Echocardiogram abnormal</li><li>Liver failure, narrowing of the bile vessel</li><li>Painful urination with blood in the urine</li><li>Increase of fat tissue.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is tacrolimus monohydrate.</p><p>Each hard capsule of Prograf 1 mg Hard Capsules contains tacrolimus monohydrate equivalent to 1 mg tacrolimus.</p><p>Each hard capsule of Prograf 5 mg Hard Capsules contains tacrolimus monohydrate equivalent to 5 mg tacrolimus.</p><p>The other ingredients are: <em>Capsule content:</em> Hydroxypropyl methylcellulose, croscarmellose sodium, lactose monohydrate and magnesium stearate. <em>Capsule shell:</em> Titanium dioxide, ferric oxide red (only in Prograf 5 mg) and gelatin. <em>Printing ink:</em> Opacode red (only in Prograf 1 mg) and Opacode white (only in Prograf 5 mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Prograf 1 mg Hard Capsules are opaque white hard gelatin capsules imprinted in red with "1 mg" on capsule cap and "[f] 617" on capsule body, containing white powder in HDPE bottles with desiccant.

Prograf 5 mg Hard Capsules are opaque grayish-red hard gelatin capsules imprinted in white with “5 mg” on capsule cap and “[f] 657” on capsule body, containing white powder in HDPE bottles with desiccant.

Pack size: 100 Hard capsules. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong><br />Astellas Ireland Co. Ltd.<br />Killorglin Co. Kerry V93 FC86,<br />Ireland</p><p><strong>Under licensed from&nbsp; </strong><br />Astellas Pharma International B.V.<br />Sylviusweg 62<br />2333BE Leiden<br />The Netherlands</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2022; version number SA3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي بروجراف إلى مجموعة من الأدوية تسمى مثبطات المناعة. بعد زرع الأعضاء (على سبيل المثال الكبد، الكلى، أو القلب)، سيحاول جهاز المناعة في جسمك أن يرفض العضو الجديد. يستخدم بروجراف للسيطرة على الاستجابة المناعية في الجسم ليتمكن جسمك من تقبل العضو المزروع.</p><p dir="RTL">غالباً ما يستخدم بروجراف بالترافق مع الأدوية الأخرى التي تعمل أيضاً على كبت جهاز المناعة.</p><p dir="RTL">يمكن أيضاً أن يعطى بروجراف للرفض المستمر للكبد المزروع أوالكلى أو القلب أو أي عضو آخر أو إذا لم تتمكن أية علاجات سابقة كنت تأخذها من السيطرة على هذه الاستجابة المناعية بعد الزرع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول بروجراف </strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية (فرط التحسس) لتاكروليموس أو لأي من المواد المستخدمة في تركيبة بروجراف (المدرجة في القسم 6).</li><li>إذا كنت تعاني من حساسية (فرط التحسس) لأي من المضادات الحيوية التي تنتمي للماكروليدات (مثل الإريثروميسين، كلاريثروميسين، جوساميسين).</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong><br />تحدث مع طبيبك، الصيدلي قبل استخدام بروجراف.</p><ul dir="rtl"><li>سوف تحتاج إلى تناول بروجراف كل يوم طالما كنت بحاجة لكبت المناعة لمنع رفض العضو المزروع. يجب أن تبقى على اتصال منتظم مع طبيبك.</li><li>قد يرغب طبيبك في إجراء عدد من الفحوصات لك أثناء تناولك بروجراف (بما في ذلك فحوصات الدم، البول، وظيفة القلب وفحوصات البصر والفحوصات العصبية) من وقت لآخر. إن هذا أمر طبيعي جداً وسوف يساعدك الطبيب في تحديد الجرعة الأنسب لك من بروجراف. &nbsp;</li><li>يرجى تجنب تناول أية علاجات عشبية، على سبيل المثال نبتة سانت جونز (هايبيريكوم بيرفوراتوم) أو أي من المستحضرات العشبية الأخرى لأن هذا قد يؤثر على فعالية وجرعة بروجراف التي تحتاج لتناولها. إذا كنت في شك يرجى استشارة الطبيب قبل تناول أية مستحضرات عشبية.</li><li>إذا كان لديك اضطرابات في الكبد أو تعاني من مرض يمكن ان يؤثر على الكبد، الرجاء إخبار الطبيب إذ قد يؤثر ذلك على جرعة بروجراف التي تتلقاها.</li><li>إذا كنت تشعر بالآم شديدة في البطن مصحوبة بأعراض أخرى، مثل القشعريرة، الحمى، الغثيان أو القيء.</li><li>إذا كنت تعاني من الإسهال لأكثر من يوم واحد، الرجاء إخبار الطبيب، لأنه قد يكون من الضروري تعديل جرعة بروجراف التي تتلقاها.</li><li>إذا كنت تعاني من تغيير في النشاط الكهربي لقلبك والذي يسمى &quot;تمديد الفترة الفاصلة QT&quot;.</li><li>ينصح بالحد من التعرض لأشعة الشمس والأشعة فوق البنفسجية أثناء تناول بروجراف من خلال ارتداء الملابس الواقية المناسبة واستخدام كريم واقي الشمس مع عامل حماية عالية من الشمس.&nbsp; وذلك بسبب زيادة خطر حصول التغيرات الجلدية الخبيثة مع علاج كبت المناعة.</li><li>إذا كنت بحاجة لأخذ أية لقاح، الرجاء إبلاغ الطبيب مسبقاً. سوف ينصحك طبيبك حول أفضل الإجراءات المناسبة.</li><li>تم الإبلاغ عن ازدياد خطورة حدوث الاضطرابات التكاثرية اللمفية لدى المرضى الذين يتناولون بروجراف (انظر القسم 4). اسأل طبيبك عن الاستشارة المتخصصة لهذه الاضطرابات.</li><li>إذا كنت مصاب أو أصبت سابقاً بتلف بالشريان الأصغر، والمعروف باسم اعْتِلالُ&nbsp;الأَوعِيَةِ&nbsp;الدَّقيقَةِ&nbsp;الخُثارِيّ/ اعتلال الفرفرية قليلة الصفيحات الخثارية/ المتلازمة&nbsp;الانحلالية الدموية البولية. أخبر طبيبك إذا ظهر لديك حمى، كدمات تحت الجلد (والتي قد تظهر على شكل بقع حمراء)، تعب غير مفسر، ارتباك، اصصفرار الجلد أو العينين، انخفاض كمية التبول، فقدان الرؤية والنوبات (انظر القسم 4). قد تزيد نسبة حدوث الأعراض المذكورة في حال تناول تاكروليماس مع ساروليماس أو إيفاروليماس.</li></ul><p dir="RTL"><strong>احتياطات التعامل: </strong><br />يجب تجنب أي اتصال مباشر مع أي جزء من جسمك مثل الجلد أو العينين، أو التنفس في محلول الحقن أو المسحوق أو الحبيبات الموجودة في مستحضرات تاكروليموس خلال التحضير. في حال حدوث اتصال كهذا قم بغسل الجلد والعينين.</p><p dir="RTL"><strong>الأدوية الأخرى وبروجراف</strong><br />يجب استشارة طبيبك أو الصيدلي إذا كنت تأخذ أو أخذت مؤخراً أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية والعلاجات العشبية.</p><p dir="RTL">يجب عدم تناول بروجراف مع سيكلوسبورين.</p><p dir="RTL">إذا احتجت مراجعة طبيب غير أخصائي الزرع الخاص بك، أخبر طبيبك بأنك تتناول تاكروليموس. قد يحتاج طبيبك استشارة أخصائي الزرع الخاص بك في حال كان يجب عليك استخدام دواء آخر من الممكن أن يزيد أو يقلل من مستوى تاكروليموس في الدم.</p><p dir="RTL">يمكن أن تتأثر مستويات بروجراف في الدم ببعض الأدوية الأخرى التي تأخذها، ويمكن أن تتأثر مستويات الدم للأدوية الأخرى ببروجراف، وقد يتطلب ذلك ايقاف بروجراف، أو زيادة أو خفض الجرعة.</p><p dir="RTL">من الممكن أن يعانى بعض المرضى من ارتفاع مستويات تاكروليموس في الدم &nbsp;أثناء تناول تناول أدوية أخرى. من الممكن أن يؤدي ذلك لحدوث آثار جانبية خطيرة، مثل مشاكل الكلى، مشاكل الجهاز العصبي واضطراب ضربات القلب (انظر القسم 4).</p><p dir="RTL">قد يحدث تأثير على مستويات بروجراف في الدم بعد فترة قصيرة بعد البدء باستخدام الأدوية الأخرى، لذلك قد تحتاج للمراقبة المتكررة المتواصلة لمستويات بروجراف في الدم خلال الأيام القليلة الأولى من البدء بالعلاج بدواء آخر وتكراراً خلال الاستمرار بالعلاج بدواء آخر. قد تسبب الأدوية الأخرى انخفاض في مستويات تاكروليموس في الدم، الذي قد يزيد من خطورة رفض العضو المزروع.</p><p dir="RTL">&nbsp;تحديداً، يجب أن تخبر طبيبك إذا كنت تأخذ أو أخذت مؤخراً أدوية مع مواد فعالة مثل:</p><ul dir="rtl"><li>الأدوية المضادة للفطريات والمضادات الحيوية، خاصة المضادات المسماة الماكروليدات، التي تستخدم لعلاج العدوى مثل الكيتوكونازول، الفلوكونازول، الايتراكونازول، البوساكونازول، الفوريكونازول، الكلوتريمازول والإيزافوكونازول، الميكونازول، كاسبوفنجن، التيليثرومايسين، الاريثروميسين، الكلاريثروميسين، الجوساميسين، الازيثروميسين والريفامبيسين، الريفابيوتن، الآيزونيازيد وفلوكلاكسيلين.</li><li>ليتيرموڤير، يستخدم لمنع المرض الناتج عن الڤيروس المضخم للخلايا البشري.</li><li>مثبطات بروتياز فيروس نقص المناعة البشرية (مثل ريتونافير، نلفينافير، ساكوينافير)، الدواء المعزز كوبيسيستات وتوليفة الأقراص أو الأدوية غير النيوكليوزيدية المضادة لأنزيم المنتسخة المعاكس لفيروس نقص المناعة البشرية (إيفافيرينز، إترافيرين، نيفيرابين) التي تستخدم لعلاج عدوى فيروس نقص المناعة البشرية.</li><li>مثبطات بروتياز فيروس الالتهاب الكبدي ج (مثل التيلابريفير، وبوسيبريفير وتوليفة أومبيتاسفير/باريتابريفير/ريتونافير مع أو دون داسابوفير، إلباسفير/جرازوبريفير، وجليكابريفير/بابرينتاسفير)، التي تستخدم لعلاج عدوى التهاب الكبد الوبائي ج.</li><li>نيلوتينيب وإيماتينيب، أديلاليسيب، سيريتينيب، كريزوتينيب، أبالوتامايد، إينزالوتامايد، أو ميتُوتان (تستخدم لعلاج نوع معين من السرطان).</li><li>حمض الميكوفنوليك، يستخدم لتثبيط جهاز المناعة لمنع رفض زراعة العضو.</li><li>أدوية علاج قرحة المعدة وارتجاع الحامض (مثل أوميبرازول، لانزوبرازول، أو سيميتيدين).</li><li>مضادات القيء، التي تستخدم لعلاج الغثيان والقيء (مثل ميتوكلوبراميد)</li><li>مضاد الحموضة هيدروكسيد المغنيسيوم والألومنيوم، الذي يستخدم لعلاج الحرقة.</li><li>العلاجات الهرمونية بإيثينيل إستراديول (مثل حبوب منع الحمل) أو دانازول</li><li>الأدوية المستخدمة لعلاج ارتفاع ضغط الدم أو مشاكل القلب مثل نيفيديبين، نيكارديبين، ديلتيازيم وفيراباميل</li><li>الأدوية المضادة لاضطراب نظم القلب (اميودارون) الذي يستخدم للسيطرة على عدم انتظام ضربات القلب (دقات غير متكافئة للقلب).</li><li>الأدوية المعروفة باسم &quot;الستاتينات&quot; المستخدمة في علاج ارتفاع الكولسترول والدهون الثلاثية.</li><li>أدوية الصرع مثل الكاربامازبين، الفينيتوين أو الفينوباربيتال.</li><li>ميتاميزول، يستخدم لعلاج الألم والحمى.</li><li>الستيرويدات القشرية مثل بريدنيزولون والميثيلبريدنيزولون.</li><li>مضاد الإكتئاب نيفازودون.</li><li>المستحضرات العشبية التي تحتوي على نبتة سانت جونز وورت (هيبريكوم بيرفوراتوم) أو مستخلصات شيساندرا سفينانثيرا.</li><li>كانابيديول (استخدامات متعددة من ضمنها علاج التشنجات).</li></ul><p dir="RTL">أخبر طبيبك إذا كنت تتلقى العلاج الالتهاب الكبدي ج قد يؤدي علاج الالتهاب الكبدي ج بالأدوية إلى تغيير وظيفة الكبد لديك وقد يؤثر على مستويات تاكروليموس في الدم. قد تنقص أو تزيد مستويات تاكروليموس في الدم اعتماداً على الأدوية الموصوفة للالتهاب الكبدي ج. قد يحتاج طبيبك لمراقبة مستويات تاكروليموس في الدم عن قرب وبتعديلات ضرورية لجرعة بروجراف قبل بدء علاج الالتهاب الكبد ج.</p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ أو بحاجة إلى أخذ أيبوبروفين، الأمفوتيريسين ب، المضادات الحيوية (كوتريموكسازول، ڤانكومايسين، أو ما يسمى بالمضادات الحيوية الأمينوجليكوزايدية مثل جنتامايسين)، أو مضادات الفيروسات (مثل أسيكلوڤير، جانسيكلوڤير، سايدوفوڤير أو فوسكارنيت). قد يؤدي تناول هذه الأدوية مع بروجراف إلى تفاقم مشاكل الكلى أو الجهاز العصبي.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول ساروليماس أو إيفاروليماس. قد يزداد خطر حدوث اعْتِلالُ&nbsp;الأَوعِيَةِ&nbsp;الدَّقيقَةِ&nbsp;الخُثارِيّ، الفُرْفُرِيَّةُ القَليلَةُ الصُّفَيحاتِ الخُثارِيَّة والمتلازمة&nbsp;الانحلالية الدموية البولي عند تناول تاكروليماس بالتزامن مع ساروليماس أو إيفاروليماس (انظر القسم 4).</p><p dir="RTL">يحتاج الطبيب أيضاً لمعرفة ما إذا كنت تأخذ مكملات البوتاسيوم أو مدرات البول الموفرة للبوتاسيوم (مثل الأميلوريد، تراي أميترين أو السبيرونولاكتون)، أو المضادات الحيوية التي تزيد من مستوى البوتاسيوم في الدم مثل تريميثوبريم أو كوتريموكسازول بعض الأدوية المسكنة للألم (المسماة مضادات الالتهابات غير الستيرويدية مثل أيبوبروفين)، مضادات التخثر، أو الأدوية التي تؤخذ عن طريق الفم لمرض السكري، أثناء أخذك لبروجراف.</p><p dir="RTL">إذا كنت بحاجة إلى أي تطعيم، الرجاء إخبار طبيبك مسبقاً.</p><p dir="RTL"><strong>بروجراف مع الطعام والشراب </strong><br />بشكل عام، يجب أن تتناول بروجراف على معدة فارغة قبل ساعة على الأقل أو بعد ساعتين إلى ثلاث ساعات من تناولك الطعام. تجنب تناول الجريب فروت أو عصير الجريب فروت، أثناء العلاج ببروجراف.</p><p dir="RTL"><strong>الحمل والرضاعة </strong><br />اطلبي النصيحة من طبيبك أو الصيدلي قبل تناول هذا الدواء، إذا كنت حاملاً أو مرضعة، أوتعتقدين أنك حاملاً أو تخططين لذلك.</p><p dir="RTL">يفرز بروجراف في حليب الثدي، لذلك يجب أن لا تقومي بالإرضاع أثناء استخدامه.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />لا تقم بالقيادة أو استخدام أية أدوات أو آلات إذا كنت تشعر بالدوار أو النعاس، أو إذا أصبحت غير قادر على الرؤية بوضوح بعد تناول بروجراف. تصبح فرصة حدوث هذه الآثار أكبر إذا تناولت الكحول مع بروجراف.</p><p dir="RTL"><strong>يحتوي بروجراف على اللاكتوز</strong><strong> أحادي الماء</strong><strong>، الصوديوم والليس</strong><strong>ي</strong><strong>ثين (صويا)</strong><br />يحتوي بروجراف على اللاكتوز أحادي الماء. تحتوي كل كبسولة صلبة من بروجراف 1 ملغم و5 ملغم كبسولات صلبة على 61.35 ملغم أو 123.60 ملغم لاكتوز أحادي الماء؛ على التوالي. إذا تم إخبارك من طبيبك أن لديك عدم تحمل لبعض السكريات، اتصل بطبيك قبل تناول هذا المستحضر الدوائي.</p><p dir="RTL">يحتوي بروجراف على الصوديوم. تحتوي كل كبسولة صلبة من بروجراف 1 ملغم و5 ملغم كبسولات صلبة على 0.091 ملغم أو 0.453 ملغم صوديوم؛ على التوالي. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل كبسولة صلبة، وبذلك يمكن اعتباره &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p><p dir="RTL">يحتوي حبر الطباعة المستخدم في بروجراف 1 ملغم&nbsp;كبسولات صلبة على صويا الليسيثين. تحتوي كل كبسولة صلبة على 0.0007 ملغم صويا ليسيثين. إذا كانت لديك حساسية للفول السوداني أو الصويا، تحدث إلى طبيبك لتحديد إذا كان يجب عليك استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم بروجراف تماماً كما وصفه الطبيب. يجب استشارة الطبيب أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">تأكد من حصولك على نفس الدواء من تاكروليموس في كل مرة تقوم بصرف وصفة طبية، إلا إذا قرر اختصاصي الزرع الخاص بك على تغيير دوائك من تاكروليموس إلى نوع مختلف.</p><p dir="RTL">يجب أخذ هذا الدواء مرتين يومياً. إذا تغير شكل الدواء عن المعتاد، أو إذا تغيرت تعليمات الجرعة، تحدث إلى طبيبك أو الصيدلي في أقرب وقت ممكن للتأكد من أن لديك الدواء المناسب.</p><p dir="RTL">سيقوم الطبيب بتحديد الجرعة الابتدائية لمنع رفض العضو المزروع وذلك وفقاً لوزن جسمك. بشكل عام، ستتراوح الجرعات الأولية بعد الزرع مباشرة بين 0.075 إلى 0.30 ملغم لكل كيلوغرام من وزن الجسم يومياً اعتماداً على العضو المزروع.</p><p dir="RTL">تعتمد الجرعة على حالتك الصحية العامة وعلى نوع أدوية كبت المناعة الأخرى التي تتناولها. سيقوم طبيبك بإجراء فحوصات للدم بشكل متكرر لتحديد الجرعة الصحيحة ولتعديلها من وقت لآخر. سيقوم طبيبك بخفض جرعة بروجراف بمجرد أن تستقر حالتك. سيخبرك طبيبك بعدد وكيفية أخذ الكبسولات بالتحديد.</p><p dir="RTL">يؤخذ بروجراف عن طريق الفم مرتين يومياً، وذلك صباحاً ومساءً. بشكل عام، يجب أن تتناول بروجراف على معدة فارغة قبل ساعة على الأقل أو بعد ساعتين إلى ثلاث ساعات من تناولك الطعام. يجب ابتلاع الكبسولات بأكملها مع كوب من الماء. تناول الكبسولة فوراً بعد إزالتها من القنينة. تجنب تناول الجريب فروت أو عصير الجريب فروت، أثناء العلاج ببروجراف. لا تبتلع المادة المجففة الموجودة في غلاف القصدير.</p><p dir="RTL"><strong>إذا تناولت بروجراف أكثر من اللازم</strong><br />إذا كنت قد تناولت الكثير من بروجراف دون قصد، اتصل بطبيبك أو بأقرب قسم طوارئ في المستشفى على الفور.</p><p dir="RTL"><strong>إذا نسيت تناول بروجراف</strong><br />لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">إذا نسيت أخذ كبسولات بروجراف في موعدها، انتظر حتى موعد الجرعة التالية ومن ثم تابع تناولها كالسابق.</p><p dir="RTL"><strong>إذا توقفت عن تناول بروجراف</strong><br />وقف العلاج الخاص من بروجراف قد يزيد من خطر رفض العضو المزروع. لا تتوقف عن علاجك ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">للاستفسار أو لمزيد من المعلومات عن استخدام هذا الدواء، يرجى إستشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب بروجراف بعض الأعراض الجانبية، إلا أنها قد لا تصيب جميع المرضى.</p><p dir="RTL">يضعف بروجراف آلية الجسم الدفاعية بهدف منع رفض جسمك للعضو المزروع، وبالتالي تضعف قدرة الجسم الدفاعية ضد الإصابة بالعدوى، فيصبح الجسم أكثر عرضة للإصابة بالعدوى إذا كنت تتناول بروجراف، مثل عدوى الجلد، الفم، المعدة والأمعاء، الرئتين والمسالك البولية.</p><p dir="RTL">قد تكون بعض العدوى خطيرة أو قاتلة وقد تشمل البكتيريا، الفيروسات، الفطريات، الطفيليات أو العدوات الأخرى.</p><p dir="RTL">أخبر طبيبك على الفور إذا ظهرت لديك علامات العدوى التي تشمل:</p><ul dir="rtl"><li>حمى، سعال، التهاب الحلق، الشعور بالضعف أو التعب العام</li><li>فقدان الذاكرة، مشاكل في التفكير، صعوبة في المشي- أو فقدان الرؤية- قد يكون ذلك بسبب عدوى نادرة جداً، خطيرة في الدماغ، والتي قد تكون قاتلة (اعتلال بيضاء الدماغ متعدد البؤر التقدمي)</li></ul><p dir="RTL"><strong><em>قد تظهر لديك أعراض جانبية شديدة، من ضمنها الأعراض الجانبية المذكورة التالية. أخبر طبيبك في الحال إذا عانيت أو تعتقد أنك تعاني من أي من الآثار الجانبية الخطيرة التالية:</em><br />آثار جانبية خطيرة شائعة (قد يؤثر فيما يصل إلى 1 من كل 10 أشخاص): </strong></p><ul dir="rtl"><li>ثقب الجهاز الهضمي: آلام شديدة في البطن مصحوبة أو غير مصحوبة بأعراض أخرى مثل النفضات، الحمى، الغثيان أو التقيؤ.</li><li>وظائف غير كافية للعضو المزروع.</li><li>تغييم الرؤية.</li></ul><p dir="RTL"><strong>آثار جانبية خطيرة غير شائعة (قد يؤثر فيما يصل إلى 1 من كل 100 أشخاص): </strong></p><ul dir="rtl"><li>اعتلال الأوعية الدقيقة الخثاري (تلف في أصغر الأوعية الدموية) بما في ذلك المتلازمة&nbsp;الانحلالية الدموية البولية، حالة تشمل الأعراض التالية: قلة وعدم إخراج البول (الفشل الكلوي الحاد)، التعب الحاد، اصفرار الجلد أو العينين (اليرقان) والكدمات غير الطبيعية أو النزيف وعلامات العدوى.</li></ul><p dir="RTL"><strong>آثار جانبية خطيرة نادرة (قد يؤثر فيما يصل إلى 1 من كل 1000 أشخاص): </strong></p><ul dir="rtl"><li>الفرفرية قليلة الصفيحات الخثارية وهي حالة تشمل تلف في أصغر الأوعية الدموية وتتميز بالحمى وكدمات تحت الجلد والتي قد تظهر كنقاط حمراء صغيرة جداً، مع أو بدون تعب شديد غير مبرر، ارتباك، اصفرار الجلد أو العينين (اليرقان)، مع أعراض الفشل الكلوي الحاد (قلة وعدم إخراج البول)، فقدان الرؤية والنوبات.</li><li>تقشر الانسجة المتموًتة البشرويَة التسمُمي: تآكل وظهور تقرحات في الجلد أو الأغشية المخاطية، احمرار وتورم الجلد الذي يمكن أن ينفصل في أجزاء كبيرة من الجسم.</li><li>العمى.</li></ul><p dir="RTL"><strong>آثار جانبية خطيرة نادرة جداً (قد يؤثر فيما يصل إلى 1 من كل 10000 أشخاص): </strong></p><ul dir="rtl"><li>متلازمة ستيفنز جونسون: آلام غير مبررة في مساحات واسعة من الجلد، تورم الوجه، مرض شديد مع ظهور تقرحات في الجلد، الفم، العينين، والأعضاء التناسلية، الشرى، تورم اللسان، انتشار طفح جلدي أحمر أو أرجواني، تقشر الجلد.</li><li>مرض تورساد دي بوانتس<em>:</em> تغير في وتيرة ضربات القلب التي يمكن أن تكون مصحوبة أو غير مصحوبة بأعراض، مثل ألم في الصدر (الذبحة الصدرية)، فقدان الوعي، الدوار أو الغثيان، الخفقان (شعور بضربات القلب) وصعوبة في التنفس.</li></ul><p dir="RTL"><strong>آثار جانبية خطيرة - </strong><strong>غير معروفة</strong> <strong>التكرار</strong> <strong>(لا يمكن تقدير التكرار من البيانات المتاحة):</strong></p><ul dir="rtl"><li>العدوى الانتهازية (بكتيرية، فطرية، فيروسية، وأواليه): إسهال لفترة طويلة، الحمى والتهاب الحلق.</li><li>تم الإبلاغ عن حدوث أورام حميدة وخبيثة بعد العلاج نتيجة لكبت المناعة.</li><li>تم الابلاغ عن حالات من عدم تنسج خلايا الدم الحمراء النقي (انخفاض شديد جداً في عدد خلايا الدم الحمراء)، فقر الدم الانحلالي (انخفاض عدد خلايا الدم الحمراء بسبب التحلل غير الطبيعي المترافق مع التعب) وقلة العدلات الحموية (نقص في نوع من خلايا الدم البيضاء التي تحارب العدوى، المصحوبة بحمى). من غير المعروف تكرار حدوث هذه الآثار الجانبية بالتحديد. قد لا تعاني من الأعراض أو اعتماداً على شدة الحالة فإنك قد تشعر بـ: التعب، الخمول، شحوب غير طبيعي في الجلد، ضيق في التنفس، دوخة، صداع، آلام في الصدر وبرودة في اليدين والقدمين.</li><li>حالات من ندرة المحببات (انخفاض شديد في عدد خلايا الدم البيضاء المصحوب بتقرحات في الفم، الحمى والإصابة بالعدوى). قد لا تظهر لديك أية أعراض أو قد تشعر بحمى مفاجئة، نفضات أو التهاب الحلق.</li><li>ردود فعل تحسسية وتأقيه مع الأعراض التالية: طفح جلدي مع حكة مفاجئة (شرى)، تورم في اليدين، القدمين، الكاحل، الوجه، الشفتين، الفم أو الحلق (الذي قد يسبب صعوبة في البلع أو التنفس) وقد تشعر بفقدان الوعي.</li><li>متلازمة اعتلال الدماغ الخلفي القابل للإصلاح: الصداع، ارتباك، تغيرات المزاج، نوبات، واضطرابات بصرية. قد تدل هذه العلامات على وجود مرض يسمى متلازمة اعتلال الدماغ الخلفي القابل للإصلاح، الذي تم الإبلاغ عنه في بعض المرضى الذين تم علاجهم بتاكروليموس.</li><li>الاعتلال العصبي البصري (اضطراب في العصب البصري): مشاكل في الرؤية مثل تغييم الرؤية، تغيرات في رؤية الألوان، صعوبة في رؤية التفاصيل أو انحصار مدى الرؤية لديك.</li></ul><p dir="RTL"><strong><em>الأعراض الجانبية المدرجة أدناه قد تحدث أيضاً بعد تناولك بروجراف:</em><br />لآثار الجانبية الشائعة جداً (تؤثر على أكثر من شخص واحد من بين كل 10 أشخاص):</strong></p><ul dir="rtl"><li>زيادة نسبة السكر في الدم، داء السكري، وزيادة البوتاسيوم في الدم</li><li>صعوبة في النوم</li><li>الارتعاش، الصداع</li><li>ارتفاع ضغط الدم</li><li>وظائف كبد غير طبيعية</li><li>الإسهال، الغثيان</li><li>اضطرابات الكلى.</li></ul><p dir="RTL"><strong>الآثار الجانبية الشائعة (تؤثر فيما يصل إلى شخص واحد من بين كل 10 أشخاص):</strong></p><ul dir="rtl"><li>انخفاض في تعداد خلايا الدم (الصفيحات الدموية، خلايا الدم الحمراء أو البيضاء)، زيادة تعداد خلايا الدم البيضاء، تغيرات في تعداد خلايا الدم الحمراء (يظهر في فحوصات الدم)</li><li>انخفاض المغنيسيوم، الفوسفات، البوتاسيوم، الكالسيوم أو الصوديوم في الدم، فرط السوائل، زيادة حمض اليوريك أو الدهون في الدم، انخفاض الشهية للطعام، زيادة حموضة الدم، والتغيرات الأخرى في أملاح الدم.</li><li>أعراض القلق، الارتباك والتوهان، الاكتئاب، تغيرات في المزاج، الكوابيس، الهلوسة، والاضطرابات العقلية.</li><li>نوبات، اضطرابات في الوعي، وخز وتنميل (مؤلمة في بعض الأحيان) في اليدين والقدمين، دوخة، اعتلال في القدرة على الكتابة، واضطرابات الجهاز العصبي.</li><li>زيادة الحساسية للضوء، مشاكل في العين</li><li>صوت طنين في الأذنين</li><li>انخفاض تدفق الدم في الأوعية القلبية، زيادة سرعة ضربات القلب.</li><li>نزيف، انسداد جزئي أو كلي في الأوعية الدموية، انخفاض ضغط الدم.</li><li>ضيق في التنفس، تغيرات في أنسجة الرئة، تجمع السوائل حول الرئة، التهاب البلعوم، السعال، وأعراض شبيهة الانفلونزا.</li><li>التهابات أو تقرحات تسبب آلام في البطن، أو الإسهال، نزيف في المعدة، التهاب أو تقرحات في الفم، تجمع السوائل في البطن، القيء، آلام البطن، عسر الهضم، الإمساك، الانتفاخ، تطبل البطن، البراز الرخو، مشاكل في المعدة.</li><li>تغيرات في انزيمات وعمل الكبد، اصفرار الجلد بسبب مشاكل في الكبد، تلف أنسجة الكبد، والتهاب الكبد.</li><li>الحكة، الطفح الجلدي، فقدان الشعر، حب الشباب، زيادة التعرق.</li><li>ألم في المفاصل، الأطراف، الظهر والأقدام، وتشنجات في العضلات.</li><li>تصبح وظائف الكلى غير كافية، انخفاض إنتاج البول، وعدم القدرة على التبول أو التبول المؤلم.</li><li>الضعف العام، الحمى، تجمع السوائل في الجسم، الألم وعدم الراحة، زيادة انزيم الفوسفاتيز القلوي في الدم، زيادة الوزن، الشعور باضطراب درجة الحرارة.</li></ul><p dir="RTL"><strong>الآثار الجانبية</strong><strong> غير الشائعة (تؤثر فيما يصل إلى شخص واحد من كل 100 شخص):</strong></p><ul dir="rtl"><li>تغيرات في تخثر الدم، انخفاض في عدد جميع أنواع خلايا الدم.</li><li>الجفاف</li><li>انخفاض البروتين أو السكر في الدم، ارتفاع الفوسفات في الدم</li><li>الغيبوبة، نزيف في الدماغ، السكتة الدماغية، الشلل، اضطرابات الدماغ، اعتلالات في التكلم واللغة، مشاكل في الذاكرة.</li><li>غباش في الرؤية بسبب خلل في عدسة العين.</li><li>اعتلال في السمع.</li><li>عدم انتظام ضربات القلب، وقف ضربات القلب، انخفاض في أداء القلب، اضطراب في عضلة القلب، تضخم عضلة القلب، زيادة في قوة نبض القلب، تخطيط قلب غير طبيعي، ومعدل ضربات القلب والنبض غير طبيعيين.</li><li>تجلط الدم في وريد أحد الأطراف، الصدمة.</li><li>صعوبات في التنفس، اضطرابات في الجهاز التنفسي، الربو.</li><li>انسداد القناة الهضمية، زيادة مستوى انزيم الأميلاز في الدم، ارتداد محتويات المعدة في الحلق، تأخر إفراغ المعدة.</li><li>التهاب الجلد، شعور بالحرقة عند التعرض لضوء الشمس.</li><li>اضطرابات المفاصل</li><li>عدم القدرة على التبول، ألم أثناء الحيض ونزيف حيضي غير طبيعي.</li><li>فشل بعض الأعضاء، أعراض شبيهة الإنفلونزا، زيادة الحساسية للحرارة والبرودة، الشعور بالضغط على الصدر، الشعور بالقلق الشديد أو شعور غير طبيعي، زيادة انزيم اللاكتات ديهيدروجيناز في الدم، فقدان الوزن.</li></ul><p dir="RTL"><strong>الآثار الجانبية</strong><strong> النادرة (تؤثر فيما يصل إلى شخص واحد من بين كل 1000 شخص):</strong></p><ul dir="rtl"><li>نزيف بكميات قليلة تحت الجلد بسبب تجلطات الدم</li><li>زيادة تصلب العضلات</li><li>العمى</li><li>الصمم</li><li>تجمع السوائل حول القلب</li><li>ضيق التنفس الحاد</li><li>تشكيل كيس في البنكرياس</li><li>مشاكل في تدفق الدم في الكبد</li><li>زيادة في كثافة الشعر</li><li>العطش، الهبوط، الشعور بضيق في الصدر، انخفاض الحركة، التقرحات.</li></ul><p dir="RTL"><strong>الآثار الجانبية</strong><strong> النادرة جداً (تؤثر فيما يصل إلى شخص واحد من بين كل 10000 شخص):</strong></p><ul dir="rtl"><li>ضعف العضلات</li><li>اضطراب في تخطيط القلب.</li><li>فشل الكبد، تضيق الأوعية الصفراوية</li><li>التبول المؤلم المصحوب بالدم</li><li>زيادة في الأنسجة الدهنية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي تاكروليماس أحادي الماء.</p><p dir="RTL">تحتوي كل كبسولة صلبة من بروجراف 1 ملغم كبسولات صلبة على تاكروليماس أحادي الماء يكافئ 1 ملغم تاكروليماس.</p><p dir="RTL">تحتوي كل كبسولة صلبة من بروجراف 5 ملغم كبسولات صلبة على تاكروليماس أحادي الماء يكافئ 5 ملغم تاكروليماس.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>محتويات الكبسولة:</em> هيدروكسي بروبيل ميثيل السيلليلوز، كروسكارميلوز الصوديوم، لاكتوز أحادي الماء وستيرات المغنيسيوم. <em>غلاف الكبسولة:</em> ثاني أكسيد التيتانيوم، أكسيد الحديد الأحمر (في بروجراف 5 ملغم فقط) والجيلاتين. <em>حبر الطباعة:</em> أوباكود أحمر (في بروجراف 1 ملغم فقط) وأوباكود أبيض (في بروجراف 5 ملغم فقط).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">بروجراف 1 ملغم كبسولات صلبة هي كبسولات جيلاتينية صلبة معتمة ذات لون أبيض مطبوع عليها باللون الأحمر &quot;1 mg&quot; على غطاء الكبسولة و&quot;617 [f]&quot; على جسم الكبسولة، تحتوي على مسحوق أبيض في قنينات من متعدد الإيثيلين عالي الكثافة مع مادة مجففة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">بروجراف 5 ملغم كبسولات صلبة هي كبسولات جيلاتينية صلبة معتمة ذات لون أحمر رمادي مطبوع عليها باللون الأبيض &quot;5 mg&quot; على غطاء الكبسولة و&quot;657 [f]&quot; على جسم الكبسولة، تحتوي على مسحوق أبيض في قنينات من متعدد الإيثيلين عالي الكثافة مع مادة مجففة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العبوة: 100 كبسولة صلبة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة</strong><br />شركة أستيلاس إيرلندا المحدودة<br />كيلورغلين، مقاطعة كيري، V93 FC86،<br />إيرلندا&nbsp;</p><p dir="RTL"><strong>بترخيص من </strong><br />شركة أستيلاس فارما الدولية المساهمة المحدودة<br />سيلڤيوسڤخ 62<br />2333BE ليدن<br />هولندا</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي<br />مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: https://ade.sfda.gov.sa&nbsp; &nbsp;</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 11/2022؛ رقم النسخة SA3.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prograf 5 mg Hard Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule of Prograf 5 mg Hard Capsules contains tacrolimus monohydrate equivalent to 5 mg tacrolimus.

Excipient with known effect: Lactose monohydrate, sodium.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsules.

opaque grayish-red hard gelatin capsules imprinted in white with “5 mg” on capsule cap and “[f] 657” on capsule body, containing white powder
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients.</p><p>Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prograf therapy requires careful monitoring by adequately qualified and equipped personnel. The medicinal product should only be prescribed, and changes in immunosuppressive therapy initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients.</p><p>Inadvertent, unintentional or unsupervised switching of immediate- or prolonged-release formulations of tacrolimus is unsafe. This can lead to graft rejection or increased incidence of side effects, including under- or over immunosuppression, due to clinically relevant differences in systemic exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.4 and 4.8). Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic exposure to tacrolimus is maintained.</p><p><strong>General considerations</strong></p><p>The recommended initial dosages presented below are intended to act solely as a guideline. Prograf dosing should primarily be based on clinical assessments of rejection and tolerability in each patient individually aided by blood level monitoring (see below for recommended target whole blood trough concentrations). If clinical signs of rejection are apparent, alteration of the immunosuppressive regimen should be considered.</p><p>Prograf can be administered intravenously or orally. In general, dosing may commence orally; if necessary, by administering the capsule contents suspended in water, via nasogastric tubing.</p><p>Prograf is routinely administered in conjunction with other immunosuppressive agents in the initial post-operative period. The Prograf dose may vary depending upon the immunosuppressive regimen chosen.</p><p><strong>Posology</strong></p><p><u>Dosage recommendations &ndash; Liver transplantation</u></p><p><em>Prophylaxis of transplant rejection - adults</em></p><p>Oral Prograf therapy should commence at 0.10 - 0.20 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence approximately 12 hours after the completion of surgery.</p><p>If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.01 - 0.05 mg/kg/day should be initiated as a continuous 24-hour infusion.</p><p><em>Prophylaxis of transplant rejection - children</em></p><p>An initial oral dose of 0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening). If the clinical condition of the patient prevents oral dosing, an initial intravenous dose of 0.05 mg/kg/day should be administered as a continuous 24-hour infusion.</p><p><em>Dose adjustment during post-transplant period in adults and children</em></p><p>Prograf doses are usually reduced in the post-transplant period. It is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to Prograf monotherapy. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><em>Rejection therapy &ndash; adults and children</em></p><p>Increased Prograf doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity are noted (e.g. pronounced adverse reactions - see section 4.8) the dose of Prograf may need to be reduced.</p><p>For conversion to Prograf, treatment should begin with the initial oral dose recommended for primary immunosuppression.</p><p>For information on conversion from ciclosporin to Prograf, see below under &ldquo;Dose adjustments in specific patient populations&rdquo;.</p><p><u>Dosage recommendations - Kidney transplantation</u></p><p><em>Prophylaxis of transplant rejection &ndash; adults</em></p><p>Oral Prograf therapy should commence at 0.20 - 0.30 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence within 24 hours after the completion of surgery.</p><p>If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.05 - 0.10 mg/kg/day should be initiated as a continuous 24-hour infusion.</p><p><em>Prophylaxis of transplant rejection &ndash; children</em></p><p>An initial oral dose of 0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening). If the clinical condition of the patient prevents oral dosing, an initial intravenous dose of 0.075 &ndash; 0.100 mg/kg/day should be administered as a continuous 24-hour infusion.</p><p><em>Dose adjustment during post-transplant period in adults and children</em></p><p>Prograf doses are usually reduced in the post-transplant period. It is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to Prograf-based dual-therapy. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><em>Rejection therapy &ndash; adults and children</em></p><p>Increased Prograf doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity are noted (e.g. pronounced adverse reactions - see section 4.8) the dose of Prograf may need to be reduced.</p><p>For conversion to Prograf, treatment should begin with the initial oral dose recommended for primary immunosuppression.</p><p>For information on conversion from ciclosporin to Prograf, see below under &ldquo;Dose adjustments in specific patient populations&rdquo;.</p><p><u>Dosage recommendations - Heart transplantation</u></p><p><em>Prophylaxis of transplant rejection &ndash; adults</em></p><p>Prograf can be used with antibody induction (allowing for delayed start of Prograf therapy) or alternatively in clinically stable patients without antibody induction.</p><p>Following antibody induction, oral Prograf therapy should commence at a dose of 0.075 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence within 5 days after the completion of surgery as soon as the patient&#39;s clinical condition is stabilised. If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.01 to 0.02 mg/kg/day should be initiated as a continuous 24-hour infusion.</p><p>An alternative strategy was published where oral tacrolimus was administered within 12 hours post transplantation. This approach was reserved for patients without organ dysfunction (e.g. renal dysfunction). In that case, an initial oral tacrolimus dose of 2 to 4 mg per day was used in combination with mycophenolate mofetil and corticosteroids or in combination with sirolimus and corticosteroids.</p><p><em>Prophylaxis of transplant rejection &ndash; children</em></p><p>Prograf has been used with or without antibody induction in paediatric heart transplantation.</p><p>In patients without antibody induction, if Prograf therapy is initiated intravenously, the recommended starting dose is 0.03 - 0.05 mg/kg/day as a continuous 24-hour infusion targeted to achieve tacrolimus whole blood concentrations of 15 - 25 ng/ml. Patients should be converted to oral therapy as soon as clinically practicable. The first dose of oral therapy should be 0.30 mg/kg/day starting 8 to 12 hours after discontinuing intravenous therapy.</p><p>Following antibody induction, if Prograf therapy is initiated orally, the recommended starting dose is 0.10 - 0.30 mg/kg/day administered as two divided doses (e.g. morning and evening).</p><p><em>Dose adjustment during post-transplant period in adults and children</em></p><p>Prograf doses are usually reduced in the post-transplant period. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><em>Rejection therapy &ndash; adults and children</em></p><p>Increased Prograf doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes.</p><p>In adult patients converted to Prograf, an initial oral dose of 0.15 mg/kg/day should be administered in two divided doses (e.g. morning and evening).</p><p>In paediatric patients converted to Prograf, an initial oral dose of 0.20 - 0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening).</p><p>For information on conversion from ciclosporin to Prograf, see below under &ldquo;Dose adjustments in specific patient populations&rdquo;.</p><p><em>Dosage recommendations - Rejection therapy, other allografts</em></p><p>The dose recommendations for lung, pancreas and intestinal transplantation are based on limited prospective clinical trial data. In lung-transplanted patients Prograf has been used at an initial oral dose of 0.10 - 0.15 mg/kg/day, in pancreas-transplanted patients at an initial oral dose of 0.2 mg/kg/day and in intestinal transplantation at an initial oral dose of 0.3 mg/kg/day.</p><p><u>Dosage adjustments in specific patient populations</u></p><p><em>Patients with liver impairment</em></p><p>Dose reduction may be necessary in patients with severe liver impairment in order to maintain the blood trough levels within the recommended target range.</p><p><em>Patients with kidney impairment</em></p><p>As the pharmacokinetics of tacrolimus are unaffected by renal function, no dose adjustment should be required. However, owing to the nephrotoxic potential of tacrolimus careful monitoring of renal function is recommended (including serial serum creatinine concentrations, calculation of creatinine clearance and monitoring of urine output).</p><p><em>Paediatric population</em></p><p>In general, paediatric patients require doses 1&frac12; - 2 times higher than the adult doses to achieve similar blood levels.</p><p><em>Older people</em></p><p>There is no evidence currently available to indicate that dosing should be adjusted in older people.</p><p><u>Conversion from ciclosporin</u></p><p>Care should be taken when converting patients from ciclosporin-based to Prograf-based therapy (see sections 4.4 and 4.5). Prograf therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient. Dosing should be delayed in the presence of elevated ciclosporin blood levels. In practice, Prograf therapy has been initiated 12 - 24 hours after discontinuation of ciclosporin. Monitoring of ciclosporin blood levels should be continued following conversion as the clearance of ciclosporin might be affected.</p><p><u>Target whole blood trough concentration recommendations</u></p><p>Dosing should primarily be based on clinical assessments of rejection and tolerability in each individual patient.</p><p>As an aid to optimise dosing, several immunoassays are available for determining tacrolimus concentrations in whole blood including a semi-automated microparticle enzyme immunoassay (MEIA). Comparisons of concentrations from the published literature to individual values in clinical practice should be assessed with care and knowledge of the assay methods employed. In current clinical practice, whole blood levels are monitored using immunoassay methods.</p><p>Blood trough levels of tacrolimus should be monitored during the post-transplantation period. When dosed orally, blood trough levels should be drawn approximately 12 hours post-dosing, just prior to the next dose. The frequency of blood level monitoring should be based on clinical needs. As Prograf is a medicinal product with low clearance, adjustments to the dosage regimen may take several days before changes in blood levels are apparent. Blood trough levels should be monitored approximately twice weekly during the early post-transplant period and then periodically during maintenance therapy. Blood trough levels of tacrolimus should also be monitored following dose adjustment, changes in the immunosuppressive regimen, or following co-administration of substances which may alter tacrolimus whole blood concentrations (see section 4.5).</p><p>Clinical study analysis suggests that the majority of patients can be successfully managed if tacrolimus blood trough levels are maintained below 20 ng/ml. It is necessary to consider the clinical condition of the patient when interpreting whole blood levels.</p><p>In clinical practice, whole blood trough levels have generally been in the range 5 - 20 ng/ml in liver transplant recipients and 10 - 20 ng/ml in kidney and heart transplant patients in the early post-transplant period. Subsequently, during maintenance therapy, blood concentrations have generally been in the range of 5 - 15 ng/ml in liver, kidney and heart transplant recipients.</p><p><strong>Method of administration</strong></p><p>It is recommended that the oral daily dose be administered in two divided doses (e.g. morning and evening). Capsules should be taken immediately following removal from the bottle. Patients should be advised not to swallow the desiccant. The capsules should be swallowed with fluid (preferably water).</p><p>Capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption (see section 5.2).</p><p><strong>Duration of dosing</strong></p><p>To suppress graft rejection, immunosuppression must be maintained; consequently, no limit to the duration of oral therapy can be given.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to tacrolimus or other macrolides.

Hypersensitivity to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. This has led to serious adverse events, including graft rejection, or other side effects which could be a consequence of either under- or over-exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.2 and 4.8).</p><p>During the initial post-transplant period, monitoring of the following parameters should be undertaken on a routine basis: blood pressure, ECG, neurological and visual status, fasting blood glucose levels, electrolytes (particularly potassium), liver and renal function tests, haematology parameters, coagulation values, and plasma protein determinations. If clinically relevant changes are seen, adjustments of the immunosuppressive regimen should be considered.</p><p><u>Substances with potential for interaction</u></p><p>Inhibitors or inducers of CYP3A4 should only be co-administered with tacrolimus after consulting a transplant specialist, due to the potential for drug interactions resulting in serious adverse reactions including rejection or toxicity (see section 4.5).</p><p><em>CYP3A4 inhibitors</em></p><p>Concomitant use with CYP3A4 inhibitors may increase tacrolimus blood levels, which could lead to serious adverse reactions, including nephrotoxicity, neurotoxicity and QT prolongation. It is recommended that concomitant use of strong CYP3A4 inhibitors (such as ritonavir, cobicistat,</p><p>ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin or josamycin) with tacrolimus should be avoided. If unavoidable, tacrolimus blood levels should be monitored frequently, starting within the first few days of coadministration, under the supervision of a transplant specialist, to adjust the tacrolimus dose if appropriate in order to maintain similar tacrolimus exposure.</p><p>Renal function, ECG including the QT interval, and the clinical condition of the patient should also be closely monitored.</p><p>Dose adjustment needs to be based upon the individual situation of each patient. An immediate dose reduction at the time of treatment initiation may be required (see section 4.5).</p><p>Similarly, discontinuation of CYP3A4 inhibitors may affect the rate of metabolism of tacrolimus,</p><p>thereby leading to subtherapeutic blood levels of tacrolimus, and therefore requires close monitoring and supervision of a transplant specialist.</p><p><em>CYP3A4 inducers</em></p><p>Concomitant use with CYP3A4 inducers may decrease tacrolimus blood levels, potentially increasing the risk of transplant rejection. It is recommended that concomitant use of strong CYP3A4 inducers (such as rifampicin, phenytoin, carbamazepine), with tacrolimus should be avoided. If unavoidable, tacrolimus blood levels should be monitored frequently, starting within the first few days of coadministration, under the supervision of a transplant specialist, to adjust the tacrolimus dose if appropriate, in order to maintain similar tacrolimus exposure. Graft function should also be closely monitored (see section 4.5).</p><p>Similarly, discontinuation of CYP3A4 inducers may affect the rate of metabolism of tacrolimus, thereby leading to supratherapeutic blood levels of tacrolimus, and therefore requires close monitoring and supervision of a transplant specialist.</p><p><em>P-glycoprotein</em></p><p>Caution should be observed when co-administering tacrolimus with drugs that inhibit P-glycoprotein, as an increase in tacrolimus levels may occur. Tacrolimus whole blood levels and the clinical condition of the patient should be monitored closely. An adjustment of the tacrolimus dose may be required (see section 4.5).</p><p><em>Herbal preparations</em></p><p>Herbal preparations containing St. John&rsquo;s wort (<em>Hypericum perforatum</em>) or other herbal preparations should be avoided when taking Prograf due to the risk of interactions that lead to either a decrease in blood concentrations of tacrolimus and reduced clinical effect of tacrolimus, or an increase in blood concentrations of tacrolimus and risk of tacrolimus toxicity (see section 4.5).</p><p><em>Other interactions</em></p><p>The combined administration of ciclosporin and tacrolimus should be avoided and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.5).</p><p>High potassium intake or potassium-sparing diuretics should be avoided (see section 4.5).</p><p>Certain combinations of tacrolimus with drugs known to have neurotoxic effects may increase the risk of these effects (see section 4.5).</p><p>Vaccination</p><p>Immunosuppressants may affect the response to vaccination and vaccination during treatment with tacrolimus may be less effective. The use of live attenuated vaccines should be avoided.</p><p><u>Nephrotoxicity</u></p><p>Tacrolimus can result in renal function impairment in post-transplant patients. Acute renal impairment without active intervention may progress to chronic renal impairment. Patients with impaired renal function should be monitored closely as the dosage of tacrolimus may need to be reduced. The risk for nephrotoxicity may increase when tacrolimus is concomitantly administered with drugs associated with nephrotoxicity (see section 4.5). Concurrent use of tacrolimus with drugs known to have nephrotoxic effects should be avoided. When co-administration cannot be avoided, tacrolimus trough blood level and renal function should be monitored closely and dosage reduction should be considered if nephrotoxicity occurs.</p><p><u>Gastrointestinal disorders</u></p><p>Gastrointestinal perforation has been reported in patients treated with tacrolimus. As gastrointestinal perforation is a medically important event that may lead to a life-threatening or serious condition, adequate treatments should be considered immediately after suspected symptoms or signs occur.</p><p>Since levels of tacrolimus in blood may significantly change during diarrhoea episodes, extra monitoring of tacrolimus concentrations is recommended during episodes of diarrhoea.</p><p><u>Cardiac disorders</u></p><p>Ventricular hypertrophy or hypertrophy of the septum, reported as cardiomyopathies, have been observed on rare occasions. Most cases have been reversible, occurring primarily in children with tacrolimus blood trough concentrations much higher than the recommended maximum levels. Other factors observed to increase the risk of these clinical conditions included pre-existing heart disease, corticosteroid usage, hypertension, renal or hepatic dysfunction, infections, fluid overload, and oedema. Accordingly, high-risk patients, particularly young children and those receiving substantial immunosuppression should be monitored, using such procedures as echocardiography or ECG pre- and post-transplant (e.g. initially at three months and then at 9-12 months). If abnormalities develop, dose reduction of Prograf therapy, or change of treatment to another immunosuppressive agent should be considered. Tacrolimus may prolong the QT interval and may cause&nbsp;<em>Torsades de Pointes</em>. Caution should be exercised in patients with risk factors for QT prolongation, including patients with a personal or family history of QT prolongation, congestive heart failure, bradyarrhythmias and electrolyte abnormalities. Caution should also be exercised in patients diagnosed or suspected to have Congenital Long QT Syndrome or acquired QT prolongation or patients on concomitant medications known to prolong the QT interval, induce electrolyte abnormalities or known to increase tacrolimus exposure (see section 4.5).</p><p><u>Lymphoproliferative disorders and malignancies</u></p><p>Patients treated with Prograf have been reported to develop Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (see section 4.8). Patients switched to Prograf therapy should not receive anti-lymphocyte treatment concomitantly. Very young (&lt; 2 years), EBV-VCA-negative children have been reported to have an increased risk of developing lymphoproliferative disorders. Therefore, in this patient group, EBV-VCA serology should be ascertained before starting treatment with Prograf. During treatment, careful monitoring with EBV-PCR is recommended. Positive EBV-PCR may persist for months and is per se not indicative of lymphoproliferative disease or lymphoma.</p><p>As with other immunosuppressive agents, owing to the potential risk of malignant skin changes, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p><p>As with other potent immunosuppressive compounds, the risk of secondary cancer is unknown (see section 4.8).</p><p><u>Posterior reversible encephalopathy syndrome (PRES)</u></p><p>Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). If patients taking tacrolimus present with symptoms indicating PRES such as headache, altered mental status, seizures, and visual disturbances, a radiological procedure (e.g. MRI) should be performed. If PRES is diagnosed, adequate blood pressure and seizures control and immediate discontinuation of systemic tacrolimus is advised. Most patients completely recover after appropriate measures are taken.</p><p><u>Eye disorders</u></p><p>Eye disorders, sometimes progressing to loss of vision, have been reported in patients treated with tacrolimus. Some cases have reported resolution on switching to alternative immunosuppression. Patients should be advised to report changes in visual acuity, changes in colour vision, blurred vision, or visual field defect, and in such cases, prompt evaluation is recommended with referral to an ophthalmologist as appropriate.</p><p><u>Infections including opportunistic infections</u></p><p>Patients treated with immunosuppressants, including Prograf are at increased risk for infections including opportunistic infections (bacterial, fungal, viral and protozoal) such as CMV infections, BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML). Patients are also at an increased risk of infections with viral hepatitis (for example, hepatitis B and C reactivation and de novo infection, as well as hepatitis E, which may become chronic). These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions including graft rejection&nbsp; that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating hepatic or renal function or neurological symptoms.</p><p>Prevention and management should be in accordance with appropriate clinical guidance.</p><p><u>Thrombotic microangiopathy (TMA) (including haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP))</u></p><p>The diagnosis of TMA, including thrombotic thrombocytopaenic purpura (TTP) and haemolytic uraemic syndrome (HUS), sometimes leading to renal failure or a fatal outcome, should be considered in patients presenting with haemolytic anaemia, thrombocytopenia, fatigue, fluctuating neurological manifestation, renal impairment, and fever. If TMA is diagnosed, prompt treatment is required, and discontinuation of tacrolimus should be considered at the discretion of the treating physician.</p><p>The concomitant administration of tacrolimus with a mammalian target of rapamycin (mTOR) inhibitor (e.g., sirolimus, everolimus) may increase the risk of thrombotic microangiopathy (including haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura).</p><p><u>Pure Red Cell Aplasia</u></p><p>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with tacrolimus. All patients reported risk factors for PRCA such as parvovirus B19 infection, underlying disease or concomitant medications associated with PRCA.</p><p><u>Excipients</u></p><p>Prograf contains lactose monohydrate. Each hard capsule of Prograf 5 mg Hard Capsules contains 123.60 mg lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Prograf contains sodium. Each hard capsule of Prograf 5 mg Hard Capsules contains 0.453 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Metabolic interactions</u></p><p>Systemically available tacrolimus is metabolised by hepatic CYP3A4. There is also evidence of gastrointestinal metabolism by CYP3A4 in the intestinal wall. Concomitant use of medicinal products or herbal remedies known to inhibit or induce CYP3A4 may affect the metabolism of tacrolimus and thereby increase or decrease tacrolimus blood levels. Similarly, discontinuation of such products or herbal remedies may affect the rate of metabolism of tacrolimus and thereby the blood levels of tacrolimus.</p><p>Pharmacokinetics studies have indicated that the increase in tacrolimus blood levels when coadministered with inhibitors of CYP3A4 is mainly a result of increase in oral bioavailability of tacrolimus owing to the inhibition of gastrointestinal metabolism. Effect on hepatic clearance is less pronounced.</p><p>It is recommended strongly to closely monitor tacrolimus blood levels under supervision of a transplant specialist, as well as monitor for graft function, QT prolongation (with ECG), renal function and other side effects including neurotoxicity, whenever substances which have the potential to alter CYP3A4 metabolism are used concomitantly and to adjust or interrupt the tacrolimus dose if appropriate in order to maintain similar tacrolimus exposure (see sections 4.2 and 4.4). Similarly, patients should be closely monitored when using tacrolimus concomitantly with multiple substances that affect CYP3A4 as the effects on tacrolimus exposure may be enhanced or counteracted.</p><p>Medicinal products which have effects on tacrolimus are listed in the table below. The examples of drug-drug interactions are not intended to be inclusive or comprehensive and therefore the label of each drug that is co-administered with tacrolimus should be consulted for information related to the route of metabolism, interaction pathways, potential risks, and specific actions to be taken with regards to co-administration.</p><p>Medicinal products which have effects on tacrolimus</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Drug/Substance Class or Name</p></td><td style="vertical-align:top"><p>Drug interaction effect</p></td><td style="vertical-align:top"><p>Recommendations concerning co-administration</p></td></tr><tr><td style="vertical-align:top"><p>Grapefruit or grapefruit juice</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see section 4.4].</p></td><td style="vertical-align:top"><p>Avoid grapefruit or grapefruit juice.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations. In addition, synergistic/additive nephrotoxic effects can occur.</p></td><td style="vertical-align:top"><p>The simultaneous use of ciclosporin and tacrolimus should be avoided [see section 4.4].</p></td></tr><tr><td style="vertical-align:top"><p>Products known to have nephrotoxic or neurotoxic effects:</p><p>aminoglycosides, gyrase inhibitors, vancomycin, sulfamethoxazole + trimethoprim, NSAIDs, ganciclovir, acyclovir, amphotericin B, ibuprofen, cidofovir, foscarnet</p></td><td style="vertical-align:top"><p>May enhance nephrotoxic or neurotoxic effects of tacrolimus.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Concurrent use of tacrolimus with drugs known to have nephrotoxic effects should be avoided. When co-administration cannot be avoided, monitor renal function and other side effects and adjust tacrolimus dose if needed.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP3A4 inhibitors:</p><p>antifungal agents (e.g., ketoconazole, itraconazole, posaconazole, voriconazole), the macrolide antibiotics (e.g., telithromycin, troleandomycin, clarithromycin, josamycin),</p><p>HIV protease inhibitors (e.g., ritonavir, nelfinavir, saquinavir), HCV protease inhibitors (e.g. telaprevir, boceprevir, and the combination of ombitasvir and paritaprevir with ritonavir, when used with and without dasabuvir), nefazodone, the pharmacokinetic enhancer cobicistat, and the kinase inhibitors idelalisib, ceritinib.</p><p>Strong interactions have also been observed with the macrolide antibiotic erythromycin.</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., nephrotoxicity, neurotoxicity, QT prolongation) which requires close monitoring [see section 4.4].</p><p>Rapid and sharp increases in tacrolimus levels, may occur, as early as within 1-3 days after co-administration, despite immediate reduction of tacrolimus dose.</p><p>Overall tacrolimus exposure may increase &gt;5 fold. When ritonavir combinations are co-administered, tacrolimus exposure may increase &gt;50 fold.</p><p>Nearly all patients may require a reduction in tacrolimus dose and temporary interruption of tacrolimus may also be necessary.</p><p>The effect on tacrolimus blood concentrations may remain for several days after co-administration is completed.</p></td><td style="vertical-align:top"><p>It is recommended that concomitant use should be avoided. If co-administration of a strong CYP3A4 inhibitor is unavoidable, consider omitting the dose of tacrolimus the day the strong CYP3A4 inhibitor is initiated. Reinitiate tacrolimus the next day at a reduced dose based on tacrolimus blood concentrations. Changes in both tacrolimus dose and/or dosing frequency should be individualized and adjusted as needed based on tacrolimus trough concentrations, which should be assessed at initiation, monitored frequently throughout (starting within the first few days) and re-evaluated on and after completion of the CYP3A4 inhibitor. Upon completion, appropriate dose and dosing frequency of tacrolimus should be guided by tacrolimus blood concentrations. Monitor renal function, ECG for QT prolongation, and other side effects closely.</p></td></tr><tr><td style="vertical-align:top"><p>Moderate or weak CYP3A4 inhibitors:<br />antifungal agents (e.g., fluconazole, isavuconazole, clotrimazole, miconazole), the macrolide antibiotics (e.g., azithromycin), calcium channel blockers (e.g., nifedipine, nicardipine, diltiazem, verapamil), amiodarone, danazol, ethinylestradiol, lansoprazole, omeprazole, the HCV antivirals elbasvir/grazoprevir and glecaprevir/pibrentasvir, the CMV antiviral letermovir, and the tyrosine kinase inhibitors nilotinib, crizotinib, imatinib and (Chinese) herbal remedies containing extracts of Schisandra sphenanthera</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see section 4.4]. A rapid increase in tacrolimus level may occur.</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations frequently, starting within the first few days of co-administration. Reduce tacrolimus dose if needed [see section 4.2]. Monitor renal function, ECG for QT prolongation, and other side effects closely.</p></td></tr><tr><td style="vertical-align:top"><p>In vitro the following substances have been shown to be potential inhibitors of tacrolimus metabolism: bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, midazolam, nilvadipine, norethisterone, quinidine, tamoxifen</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see section 4.4].</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed [see section 4.2].</p><p>Monitor renal function, ECG for QT prolongation, and other side effects closely.</p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP3A4 inducers:</p><p>rifampicin, phenytoin carbamazepine, apalutamide,enzalutamide, mitotane, or St.</p><p>John&rsquo;s wort (<em>Hypericum perforatum</em>)</p></td><td style="vertical-align:top"><p>May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection <em>[see section 4.4].</em></p><p>Maximal effect on tacrolimus blood concentrations may be achieved 1-2 weeks after co-administration. The effect may remain 1-2 weeks after completion of the treatment.</p></td><td style="vertical-align:top"><p>It is recommended that concomitant use should be</p><p>avoided. If unavoidable, patients may require an increase in tacrolimus dose. Changes in tacrolimus dose should be individualized and adjusted as needed based on tacrolimus trough concentrations, which should be assessed at initiation, monitored frequently throughout (starting within the first few days) and re-evaluated on and after completion of the CYP3A4 inducer. After use of the CYP3A4 inducer has ended, tacrolimus dose may need to be adjusted gradually. Monitor graft function closely.</p></td></tr><tr><td style="vertical-align:top"><p>Moderate CYP3A4 inducers:<br />metamizole, phenobarbital, isoniazid, rifabutin, efavirenz, etravirine, nevirapine; weak CYP3A4 inducers:<br />flucloxacillin</p></td><td style="vertical-align:top"><p>May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see section 4.4].</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and increase tacrolimus dose if needed [see section 4.2].</p><p>Monitor graft function closely.</p></td></tr><tr><td style="vertical-align:top"><p>Caspofungin</p></td><td style="vertical-align:top"><p>May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection. Mechanism of interaction has not been confirmed</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and</p><p>increase tacrolimus dose if needed [see section 4.2].</p><p>Monitor graft function closely.</p></td></tr><tr><td style="vertical-align:top"><p>Cannabidiol (P-gp inhibitor)</p></td><td style="vertical-align:top"><p>There have been reports of increased tacrolimus blood levels during concomitant use of tacrolimus with cannabidiol.</p><p>This may be due to inhibition of intestinal P-glycoprotein, leading to increased bioavailability of tacrolimus.</p></td><td style="vertical-align:top"><p>Tacrolimus and cannabidiol should be co-administered with caution, closely monitoring for side effects. Monitor tacrolimus whole blood trough concentrations and adjust the tacrolimus dose if needed [see sections 4.2 and 4.4]</p></td></tr><tr><td style="vertical-align:top"><p>Products known to have high affinity for plasma proteins, e.g.: NSAIDs, oral anticoagulants, oral antidiabetics</p></td><td style="vertical-align:top"><p>Tacrolimus is extensively bound to plasma proteins. Possible interactions with other active substances known to have high affinity for plasma proteins should be considered.</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed [see section 4.2].</p></td></tr><tr><td style="vertical-align:top"><p>Prokinetic agents:</p><p>metoclopramide, cimetidine and magnesium-aluminiumhydroxide</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation).</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed [see section 4.2].</p><p>Monitor closely for renal function, for QT prolongation with ECG, and for other side effects.</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance doses of corticosteroids</p></td><td style="vertical-align:top"><p>May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see section 4.4].</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and increase tacrolimus dose if needed [see section 4.2].</p><p>Monitor graft function closely.</p></td></tr><tr><td style="vertical-align:top"><p>High dose prednisolone or methylprednisolone</p></td><td style="vertical-align:top"><p>May have impact on tacrolimus blood levels (increase or decrease) when administered for the treatment of acute rejection.</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed.</p></td></tr><tr><td style="vertical-align:top"><p>Direct-acting antiviral (DAA) therapy</p></td><td style="vertical-align:top"><p>May have impact on the pharmacokinetics of tacrolimus by changes in liver function during DAA therapy, related to clearance of hepatitis virus. A decrease in tacrolimus blood levels may occur.</p><p>However, the CYP3A4 inhibiting potential of some DAAs may counteract that effect or lead to increased tacrolimus blood levels.</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed to ensure continued efficacy and safety.</p></td></tr></tbody></table><p>&nbsp;</p><p>Concomitant administration of tacrolimus with a mammalian target of rapamycin (mTOR) inhibitor (e.g., sirolimus, everolimus) may increase the risk of thrombotic microangiopathy (including haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura) (see section 4.4).</p><p>As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene, or spironolactone) should be avoided (see section 4.4). Care should be taken when tacrolimus is coadministered with other agents that increase serum potassium, such as trimethoprim and cotrimoxazole (trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a potassium-sparing diuretic like amiloride. Close monitoring of serum potassium is recommended.</p><p><u>Effect of tacrolimus on the metabolism of other medicinal products</u></p><p>Tacrolimus is a known CYP3A4 inhibitor; thus concomitant use of tacrolimus with medicinal products known to be metabolised by CYP3A4 may affect the metabolism of such medicinal products.</p><p>The half-life of ciclosporin is prolonged when tacrolimus is given concomitantly. In addition, synergistic/additive nephrotoxic effects can occur. For these reasons, the combined administration of ciclosporin and tacrolimus is not recommended and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.4).</p><p>Tacrolimus has been shown to increase the blood level of phenytoin.</p><p>As tacrolimus may reduce the clearance of steroid-based contraceptives leading to increased hormone exposure, particular care should be exercised when deciding upon contraceptive measures.</p><p>Limited knowledge of interactions between tacrolimus and statins is available. Available data suggests that the pharmacokinetics of statins are largely unaltered by the co-administration of tacrolimus.</p><p>Animal data have shown that tacrolimus could potentially decrease the clearance and increase the half life of pentobarbital and phenazone.</p><p>Mycophenolic acid. Caution should be exercised when switching combination therapy from ciclosporin, which interferes with enterohepatic recirculation of mycophenolic acid, to tacrolimus, which is devoid of this effect, as this might result in changes of mycophenolic acid exposure. Drugs which interfere with mycophenolic acid&#39;s enterohepatic cycle have potential to reduce the plasma level and efficacy of mycophenolic acid. Therapeutic drug monitoring of mycophenolic acid may be appropriate when switching from ciclosporin to tacrolimus or vice versa.</p><p>Immunosuppressants may affect the response to vaccination and vaccination during treatment with tacrolimus may be less effective. The use of live attenuated vaccines should be avoided (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Human data show that tacrolimus is able to cross the placenta. Limited data from organ transplant recipients show no evidence of an increased risk of adverse effects on the course and outcome of pregnancy under tacrolimus treatment compared with other immunosuppressive medicinal products. However, cases of spontaneous abortion have been reported. To date, no other relevant epidemiological data are available. Due to the need of treatment, tacrolimus can be considered in pregnant women when there is no safer alternative and when the perceived benefit justifies the potential risk to the foetus. In case of&nbsp;<em>in utero</em>&nbsp;exposure, monitoring of the newborn for the potential adverse effects of tacrolimus is recommended (in particular the effects on the kidneys). There is a risk for premature delivery (&lt;37 week) as well as for hyperkalaemia in the newborn, which, however, normalizes spontaneously.</p><p>In rats and rabbits, tacrolimus caused embryofoetal toxicity at doses which demonstrated maternal toxicity (see section 5.3).</p><p><u>Breast-feeding</u></p><p>Human data demonstrate that tacrolimus is excreted into breast milk. As detrimental effects on the newborn cannot be excluded, women should not breast-feed whilst receiving Prograf.</p><p><u>Fertility</u></p><p>A negative effect of tacrolimus on male fertility in the form of reduced sperm counts and motility was observed in rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tacrolimus may cause visual and neurological disturbances. This effect may be enhanced if Prograf is administered in association with alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse drug reaction profile associated with immunosuppressive agents is often difficult to establish owing to the underlying disease and the concurrent use of multiple medications.</p><p>Many of the adverse drug reactions stated below are reversible and/or respond to dose reduction. Oral administration appears to be associated with a lower incidence of adverse drug reactions compared with intravenous use. Adverse drug reactions are listed below in descending order by frequency of occurrence: very common (&ge;1/10); common (&ge;1/100, &lt;1/10); uncommon (&ge;1/1,000, &lt;1/100); rare (&ge;1/10,000, &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p><u>Infections and infestations</u></p><p>As is well known for other potent immunosuppressive agents, patients receiving tacrolimus are frequently at increased risk for infections (viral, bacterial, fungal, protozoal). The course of pre-existing infections may be aggravated. Both generalised and localised infections can occur.</p><p>Cases of CMV infections, BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Prograf.</p><p><u>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</u></p><p>Patients receiving immunosuppressive therapy are at increased risk of developing malignancies. Benign as well as malignant neoplasms including EBV-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment.</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Anaemia, leukopenia, thrombocytopenia, leukocytosis, red blood cell analyses abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Coagulopathies, coagulation and bleeding analyses abnormal, pancytopenia, neutropenia, thrombotic microangiopathy</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Thrombotic thrombocytopenic purpura, hypoprothrombinaemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Pure red cell aplasia, agranulocytosis, haemolytic anaemia, febrile neutropenia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Immune system disorders</u></p><p>Allergic and anaphylactoid reactions have been observed in patients receiving tacrolimus (see section 4.4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Endocrine disorders</u></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Hirsutism</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Metabolism and nutrition disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td colspan="2" style="vertical-align:top"><p>Hyperglycaemic conditions, diabetes mellitus, hyperkalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Hypomagnesaemia, hypophosphataemia, hypokalaemia, hypocalcaemia, hyponatraemia, fluid overload, hyperuricaemia, appetite decreased, metabolic acidoses, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, other electrolyte abnormalities</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Dehydration, hypoproteinaemia, hyperphosphataemia, hypoglycaemia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Psychiatric disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td colspan="2" style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Anxiety symptoms, confusion and disorientation, depression, depressed mood, mood disorders and disturbances, nightmare, hallucination, mental disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Psychotic disorder</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Nervous system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td colspan="2" style="vertical-align:top"><p>Tremor, headache</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Seizures, disturbances in consciousness, paraesthesias and dysaesthesias, peripheral neuropathies, dizziness, writing impaired, nervous system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Coma, central nervous system haemorrhages and cerebrovascular accidents, paralysis and paresis, encephalopathy, speech and language abnormalities, amnesia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Hypertonia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Myasthenia</p><p>posterior reversible encephalopathy syndrome (PRES)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Eye disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Vision blurred, photophobia, eye disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Cataract</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Blindness</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Optic neuropathy</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Ear and labyrinth disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Hypoacusis</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Deafness neurosensory</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Hearing impaired</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Cardiac disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Ischaemic coronary artery disorders, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Ventricular arrhythmias and cardiac arrest, heart failures, cardiomyopathies, ventricular hypertrophy, supraventricular arrhythmias, palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Pericardial effusion</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p><em>Torsades de Pointes</em></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Vascular disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td colspan="2" style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Haemorrhage, thrombembolic and ischaemic events, peripheral vascular disorders, vascular hypotensive disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Infarction, venous thrombosis deep limb, shock</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Respiratory, thoracic and mediastinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Dyspnoea, parenchymal lung disorders, pleural effusion, pharyngitis, cough, nasal congestion and inflammations</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Respiratory failures, respiratory tract disorders, asthma</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Acute respiratory distress syndrome</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td colspan="2" style="vertical-align:top"><p>Diarrhoea, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Gastrointestinal inflammatory conditions, gastrointestinal ulceration and perforation, gastrointestinal haemorrhages, stomatitis and ulceration, ascites, vomiting, gastrointestinal and abdominal pains, dyspeptic signs and symptoms, constipation, flatulence, bloating and distension, loose stools, gastrointestinal signs and symptoms</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Ileus paralytic, acute and chronic pancreatitis, gastrooesophageal reflux disease, impaired gastric emptying</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Subileus, pancreatic pseudocyst</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Hepatobiliary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Cholestasis and jaundice, hepatocellular damage and hepatitis, cholangitis</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Hepatitic artery thrombosis, venoocclusive liver disease</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Hepatic failure, bile duct stenosis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Pruritus, rash, alopecias, acne, sweating increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Dermatitis, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Toxic epidermal necrolysis (Lyell&#39;s syndrome)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Stevens Johnson syndrome</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Musculoskeletal and connective tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Arthralgia, muscle spasms, pain in extremity, back pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Joint disorders</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Mobility decreased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td colspan="2" style="vertical-align:top"><p>Renal impairment</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Renal failure, renal failure acute, oliguria, renal tubular necrosis, nephropathy toxic, urinary abnormalities, bladder and urethral symptoms</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Anuria, haemolytic uraemic syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Nephropathy, cystitis haemorrhagic</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Reproductive system and breast disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Dysmenorrhoea and uterine bleeding</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>General disorders and administration site conditions</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Asthenic conditions, febrile disorders, oedema, pain and discomfort, body temperature perception disturbed</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Multi-organ failure, influenza like illness, temperature intolerance, chest pressure sensation, feeling jittery, feeling abnormal,</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>Thirst, fall, chest tightness, ulcer</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Fat tissue increased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Investigations</u></p></td></tr><tr><td style="vertical-align:top"><p>very common</p><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>liver function tests abnormal</p><p>blood alkaline phosphatase increased, weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Amylase increased, ECG investigations abnormal, heart rate and pulse investigations abnormal, weight decreased, blood lactate dehydrogenase increased</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Echocardiogram abnormal, electrocardiogram QT prolonged</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Injury, poisoning and procedural complications</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Primary graft dysfunction</p></td></tr></tbody></table><p>Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. A number of associated cases of transplant rejection have been reported (frequency cannot be estimated from available data).</p><p><u>Description of selected adverse reactions</u></p><p>Pain in extremity has been described in a number of published case reports as part of Calcineurin-Inhibitor Induced Pain Syndrome (CIPS). This typically presents as a bilateral and symmetrical, severe, ascending pain in the lower extremities and may be associated with supra-therapeutic levels of tacrolimus. The syndrome may respond to tacrolimus dose reduction. In some cases, it was necessary to switch to alternative immunosuppression.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience with overdosage is limited. Several cases of accidental overdosage have been reported; symptoms have included tremor, headache, nausea and vomiting, infections, urticaria, lethargy, increased blood urea nitrogen and elevated serum creatinine concentrations, and increase in alanine aminotransferase levels.</p><p>No specific antidote to Prograf therapy is available. If overdosage occurs, general supportive measures and symptomatic treatment should be conducted.</p><p>Based on its high molecular weight, poor aqueous solubility, and extensive erythrocyte and plasma protein binding, it is anticipated that tacrolimus will not be dialysable. In isolated patients with very high plasma levels, haemofiltration or -diafiltration have been effective in reducing toxic concentrations. In cases of oral intoxication, gastric lavage and/or the use of adsorbents (such as activated charcoal) may be helpful, if used shortly after intake.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, calcineurin inhibitors, ATC code: L04AD02</p><p><u>Mechanism of action and pharmacodynamic effects</u></p><p>At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic protein (FKBP12) which is responsible for the intracellular accumulation of the compound. The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of lymphokine genes.</p><p>Tacrolimus is a highly potent immunosuppressive agent and has proven activity in both&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;experiments.</p><p>In particular, tacrolimus inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and &gamma;-interferon) and the expression of the interleukin-2 receptor.</p><p><u>Results from published data in other primary organ transplantation</u></p><p>Prograf has evolved into an accepted treatment as primary immunosuppressive medicinal product following pancreas, lung and intestinal transplantation. In prospective published studies tacrolimus was investigated as primary immunosuppressant in approximately 175 patients following lung, 475 patients following pancreas and 630 patients following intestinal transplantation. Overall, the safety profile of tacrolimus in these published studies appeared to be similar to what was reported in the large studies, where tacrolimus was used as primary treatment in liver, kidney and heart transplantation. Efficacy results of the largest studies in each indication are summarised below.</p><p><u>Lung transplantation</u></p><p>The interim analysis of a recent multicentre study discussed 110 patients who underwent 1:1 randomisation to either tacrolimus or ciclosporin. Tacrolimus was started as continuous intravenous infusion at a dose of 0.01 to 0.03 mg/kg/day and oral tacrolimus was administered at a dose of 0.05 to 0.3 mg/kg/day. A lower incidence of acute rejection episodes for tacrolimus-versus ciclosporin-treated patients (11.5% versus 22.6%) and a lower incidence of chronic rejection, the bronchiolitis obliterans syndrome (2.86% versus 8.57%), was reported within the first year after transplantation. The 1-year patient survival rate was 80.8% in the tacrolimus and 83% in the ciclosporin group (Treede et al., 3<sup>rd</sup>&nbsp;ICI San Diego, US, 2004;Abstract 22).</p><p>Another randomised study included 66 patients on tacrolimus versus 67 patients on ciclosporin. Tacrolimus was started as continuous intravenous infusion at a dose of 0.025 mg/kg/day and oral tacrolimus was administered at a dose of 0.15 mg/kg/day with subsequent dose adjustments to target trough levels of 10 to 20 ng/ml. The 1-year patient survival was 83% in the tacrolimus and 71% in the ciclosporin group, the 2-year survival rates were 76% and 66%, respectively. Acute rejection episodes per 100 patient-days were numerically fewer in the tacrolimus (0.85 episodes) than in the ciclosporin group (1.09 episodes). Obliterative bronchiolitis developed in 21.7% of patients in the tacrolimus group compared with 38.0% of patients in the ciclosporin group (p = 0.025). Significantly more ciclosporin-treated patients (n = 13) required a switch to tacrolimus than tacrolimus-treated patients to ciclosporin (n = 2) (p = 0.02) (Keenan et al., Ann Thoracic Surg 1995;60:580).</p><p>In an additional two-centre study, 26 patients were randomised to the tacrolimus versus 24 patients to the ciclosporin group. Tacrolimus was started as continuous intravenous infusion at a dose of 0.05 mg/kg/day and oral tacrolimus was administered at a dose of 0.1 to 0.3 mg/kg/day with subsequent dose adjustments to target trough levels of 12 to 15 ng/ml. The 1-year survival rates were 73.1% in the tacrolimus versus 79.2% in the ciclosporin group. Freedom from acute rejection was higher in the tacrolimus group at 6 months (57.7% versus 45.8%) and at 1 year after lung transplantation (50% versus 33.3%) (Treede et al., J Heart Lung Transplant 2001;20:511).</p><p>The three studies demonstrated similar survival rates. The incidences of acute rejection were numerically lower with tacrolimus in all three studies and one of the studies reported a significantly lower incidence of bronchiolitis obliterans syndrome with tacrolimus.</p><p><u>Pancreas transplantation</u></p><p>A multicentre study included 205 patients undergoing simultaneous pancreas-kidney transplantation who were randomised to tacrolimus (n=103) or to ciclosporin (n=102). The initial oral per protocol dose of tacrolimus was 0.2 mg/kg/day with subsequent dose adjustments to target trough levels of 8 to 15 ng/ml by Day 5 and 5 to 10 ng/mL after Month 6. Pancreas survival at 1 year was significantly superior with tacrolimus: 91.3% versus 74.5% with ciclosporin (p &lt; 0.0005), whereas renal graft survival was similar in both groups. In total 34 patients switched treatment from ciclosporin to tacrolimus, whereas only 6 tacrolimus patients required alternative therapy (Bechstein et al., Transplantation 2004;77:1221).</p><p><u>Intestinal transplantation</u></p><p>Published clinical experience from a single centre on the use of tacrolimus for primary treatment following intestinal transplantation showed that the actuarial survival rate of 155 patients (65 intestine alone, 75 liver and intestine, and 25 multivisceral) receiving tacrolimus and prednisone was 75% at 1 year, 54% at 5 years, and 42% at 10 years. In the early years the initial oral dose of tacrolimus was 0.3 mg/kg/day. Results continuously improved with increasing experience over the course of 11 years. A variety of innovations, such as techniques for early detection of Epstein-Barr (EBV) and CMV infections, bone marrow augmentation, the adjunct use of the interleukin-2 antagonist daclizumab, lower initial tacrolimus doses with target trough levels of 10 to 15 ng/ml, and most recently allograft irradiation were considered to have contributed to improved results in this indication over time (Abu-Elmagd et al., Ann Surg 2001;234:404).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>In man tacrolimus has been shown to be able to be absorbed throughout the gastrointestinal tract. Following oral administration of Prograf capsules peak concentrations (C<sub>max</sub>) of tacrolimus in blood are achieved in approximately 1 - 3 hours. In some patients, tacrolimus appears to be continuously absorbed over a prolonged period yielding a relatively flat absorption profile. The mean oral bioavailability of tacrolimus is in the range of 20% - 25%.</p><p>After oral administration (0.30 mg/kg/day) to liver transplant patients, steady-state concentrations of Prograf were achieved within 3 days in the majority of patients.</p><p>In healthy subjects, Prograf 0.5 mg, Prograf 1 mg and Prograf 5 mg Capsules, hard have been shown to be bioequivalent, when administered as equivalent dose.</p><p>The rate and extent of absorption of tacrolimus is greatest under fasted conditions. The presence of food decreases both the rate and extent of absorption of tacrolimus, the effect being most pronounced after a high-fat meal. The effect of a high-carbohydrate meal is less pronounced.</p><p>In stable liver transplant patients, the oral bioavailability of Prograf was reduced when it was administered after a meal of moderate fat (34% of calories) content. Decreases in AUC (27%) and C<sub>max&nbsp;</sub>(50%), and an increase in t<sub>max</sub>&nbsp;(173%) in whole blood were evident.</p><p>In a study of stable renal transplant patients who were administered Prograf immediately after a standard continental breakfast the effect on oral bioavailability was less pronounced. Decreases in AUC (2 to 12%) and C<sub>max</sub>&nbsp;(15 to 38%), and an increase in t<sub>max</sub>&nbsp;(38 to 80%) in whole blood were evident.</p><p>Bile flow does not influence the absorption of Prograf.</p><p>A strong correlation exists between AUC and whole blood trough levels at steady-state. Monitoring of whole blood trough levels therefore provides a good estimate of systemic exposure.</p><p><u>Distribution and elimination</u></p><p>In man, the disposition of tacrolimus after intravenous infusion may be described as biphasic.</p><p>In the systemic circulation, tacrolimus binds strongly to erythrocytes resulting in an approximate 20:1 distribution ratio of whole blood/plasma concentrations. In plasma, tacrolimus is highly bound (&gt; 98.8%) to plasma proteins, mainly to serum albumin and &alpha;-1-acid glycoprotein.</p><p>Tacrolimus is extensively distributed in the body. The steady-state volume of distribution based on plasma concentrations is approximately 1300 l (healthy subjects). Corresponding data based on whole blood averaged 47.6 l.</p><p>Tacrolimus is a low-clearance substance. In healthy subjects, the average total body clearance (TBC) estimated from whole blood concentrations was 2.25 l/h. In adult liver, kidney and heart transplant patients, values of 4.1 l/h, 6.7 l/h and 3.9 l/h, respectively, have been observed. Paediatric liver transplant recipients have a TBC approximately twice that of adult liver transplant patients. Factors such as low haematocrit and protein levels, which result in an increase in the unbound fraction of tacrolimus, or corticosteroid-induced increased metabolism are considered to be responsible for the higher clearance rates observed following transplantation.</p><p>The half-life of tacrolimus is long and variable. In healthy subjects, the mean half-life in whole blood is approximately 43 hours. In adult and paediatric liver transplant patients, it averaged 11.7 hours and 12.4 hours, respectively, compared with 15.6 hours in adult kidney transplant recipients. Increased clearance rates contribute to the shorter half-life observed in transplant recipients.</p><p><u>Metabolism and biotransformation</u></p><p>Tacrolimus is widely metabolised in the liver, primarily by the cytochrome P450-3A4 (CYP3A4) and the cytochrome P450-3A5 (CYP3A5). Tacrolimus is also considerably metabolised in the intestinal wall. There are several metabolites identified. Only one of these has been shown<em>&nbsp;in vitro&nbsp;</em>to have immunosuppressive activity similar to that of tacrolimus. The other metabolites have only weak or no immunosuppressive activity. In systemic circulation only one of the inactive metabolites is present at low concentrations. Therefore, metabolites do not contribute to pharmacological activity of tacrolimus.</p><p><u>Excretion</u></p><p>Following intravenous and oral administration of&nbsp;<sup>14</sup>C-labelled tacrolimus, most of the radioactivity was eliminated in the faeces. Approximately 2% of the radioactivity was eliminated in the urine. Less than 1% of unchanged tacrolimus was detected in the urine and faeces, indicating that tacrolimus is almost completely metabolised prior to elimination: bile being the principal route of elimination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The kidneys and the pancreas were the primary organs affected in toxicity studies performed in rats and baboons. In rats, tacrolimus caused toxic effects to the nervous system and the eyes. Reversible cardiotoxic effects were observed in rabbits following intravenous administration of tacrolimus.</p><p>When tacrolimus is administered intravenously as rapid infusion/bolus injection at a dose of 0.1 to 1.0 mg/kg, QTc prolongation has been observed in some animal species. Peak blood concentrations achieved with these doses were above 150 ng/ml which is more than 6-fold higher than mean peak concentrations observed with Prograf in clinical transplantation.</p><p>Embryofoetal toxicity was observed in rats and rabbits and was limited to doses that caused significant toxicity in maternal animals. In rats, female reproductive function including birth was impaired at toxic dosages and the offspring showed reduced birth weights, viability and growth.</p><p>A negative effect of tacrolimus on male fertility in the form of reduced sperm counts and motility was observed in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Capsule content:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hydroxypropyl methylcellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Croscarmellose sodium</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Lactose monohydrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p><p><em>Capsule shell: </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Ferric oxide red</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Gelatin</p><p><em>Printing ink:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Opacode white</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tacrolimus is not compatible with PVC. Tubing, syringes and other equipment used to prepare or administer a suspension of Prograf capsule contents should not contain PVC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Take the hard capsules immediately following removal from the bottle.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE bottles with desiccant.</p><p>Pack size: 100 Hard capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 December 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>